<SEC-DOCUMENT>0001193125-23-159886.txt : 20230602
<SEC-HEADER>0001193125-23-159886.hdr.sgml : 20230602
<ACCEPTANCE-DATETIME>20230602163110
ACCESSION NUMBER:		0001193125-23-159886
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230531
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230602
DATE AS OF CHANGE:		20230602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		23989363

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d512290d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20230531" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-05-31_to_2023-05-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-05-31_to_2023-05-31">0001062822</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="lxrx-20230531.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-05-31_to_2023-05-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-31</xbrli:startDate> <xbrli:endDate>2023-05-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-05-31_to_2023-05-31">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt:datemonthdayyearen">May&#160;31, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-05-31_to_2023-05-31">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-05-31_to_2023-05-31">000-30111</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-05-31_to_2023-05-31">76-0474169</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction of<br />incorporation or organization)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification Number)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-05-31_to_2023-05-31">2445 Technology Forest Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-05-31_to_2023-05-31">11th Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-05-31_to_2023-05-31">The Woodlands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-05-31_to_2023-05-31">77381</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices and Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-05-31_to_2023-05-31">(281)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-05-31_to_2023-05-31">863-3000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange on<br />which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-05-31_to_2023-05-31">Common stock, par value $0.001</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-05-31_to_2023-05-31">LXRX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-05-31_to_2023-05-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Underwriting Agreement</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;31, 2023, Lexicon Pharmaceuticals, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into an Underwriting Agreement (the &#8220;<span style="text-decoration:underline">Underwriting Agreement</span>&#8221;) with Citigroup Global Markets Inc. (&#8220;<span style="text-decoration:underline">Citigroup</span>&#8221;), Jefferies LLC (&#8220;<span style="text-decoration:underline">Jefferies</span>&#8221;) and Piper Sandler&#160;&amp; Co. (&#8220;<span style="text-decoration:underline">Piper Sandler</span>&#8221;), as representatives of the several underwriters named therein (the &#8220;<span style="text-decoration:underline">Underwriters</span>&#8221;), relating to a public offering (the &#8220;<span style="text-decoration:underline">Public Offering</span>&#8221;) of 23,924,705 shares (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (&#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The price offered to the public for the Shares was $2.60 per Share (the &#8220;<span style="text-decoration:underline">Public Offering Price</span>&#8221;). Pursuant to the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 3,588,705 shares of Common Stock (the &#8220;<span style="text-decoration:underline">Option Shares</span>&#8221;) on the same terms as their purchase of the Shares. On June&#160;1, 2023, the Underwriters exercised in full their option to purchase the Option Shares. The net proceeds to the Company from the Public Offering are expected to be approximately $66.9 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing, obligations of the parties and termination provisions. Additionally, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act</span>&#8221;). The Company has also agreed with the Underwriters not to offer or sell any shares of its Common Stock (or securities convertible into or exchangeable for Common Stock), subject to certain exceptions, for a period of 60 days after the date of the Underwriting Agreement without the prior written consent of Citigroup, Jefferies and Piper Sandler. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Offering was made pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-258564)</span> (the &#8220;<span style="text-decoration:underline">Registration Statement</span>&#8221;), declared effective by the Securities and Exchange Commission on September&#160;14, 2021, and a related prospectus included in the Registration Statement, as supplemented by a preliminary prospectus supplement dated May&#160;31, 2023 and a final prospectus supplement dated May&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is attached to this Current Report on Form <span style="white-space:nowrap">8-K</span> (this &#8220;<span style="text-decoration:underline">Current Report</span>&#8221;) as Exhibit&#160;1.1, and which is incorporated herein by reference. Vinson&#160;&amp; Elkins L.L.P., counsel to the Company, delivered an opinion as to the legality of the issuance and sale of the Shares in the Public Offering, a copy of which is attached hereto as Exhibit&#160;5.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;31, 2023, the Company entered into a Purchase Agreement (the &#8220;<span style="text-decoration:underline">Purchase Agreement</span>&#8221;) with Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P. (&#8220;<span style="text-decoration:underline">Invus</span>&#8221;), Mr.&#160;Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A (collectively, the &#8220;<span style="text-decoration:underline">Invus Entities</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, an affiliate of Invus (the &#8220;<span style="text-decoration:underline">Private Placement Purchaser</span>&#8221;) has agreed to purchase, and the Company has agreed to issue to the Private Placement Purchaser on the closing date of the Public Offering, 24,152,218 shares of Common Stock at a price per share equal to Public Offering Price (the &#8220;<span style="text-decoration:underline">Concurrent Private Placement</span>&#8221; and, together with the Public Offering, the &#8220;<span style="text-decoration:underline">Offering</span>&#8221;). Pursuant to the Purchase Agreement, the Private Placement Purchaser was granted the option to purchase up to an additional 3,622,832 shares of Common Stock (the &#8220;<span style="text-decoration:underline">Private Option Shares</span>&#8221;) at the same price per share as the Public Offering Price. On June&#160;1, 2023, the Private Placement Purchaser exercised its full option to purchase the Private Option Shares. The total purchase price of the Common Stock (including the Private Option Shares) offered to the Private Placement Purchaser is expected to be approximately $72.2 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement incorporates the representations and warranties and covenants made by the Company in the Underwriting Agreement for the benefit of the Private Placement Purchaser and certain of its affiliates. The Purchase Agreement also contains customary conditions to closing, obligations of the parties and termination provisions and serves to waive certain preemptive rights held by the Invus Entities with respect to the Public Offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement is filed as Exhibit&#160;10.1 to this Current Report and is incorporated herein by reference. The description of the Purchase Agreement in this Current Report is a summary and is qualified in its entirety by the terms of the Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Relationships</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the Offering, Invus and its affiliates will hold approximately the same percentage of the Company&#8217;s outstanding Common Stock as they did before the Offering. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth under &#8220;Purchase Agreement&#8221; in Item 1.01 of this Current Report is hereby incorporated in this Item 3.02 by reference. The Concurrent Private Placement will be taken in reliance upon the exemption from the registration requirements of the Securities Act provided by Section&#160;4(a)(2) thereof. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;1, 2023, the Company issued a press release announcing the pricing of the Offering (the &#8220;<span style="text-decoration:underline">Pricing Press Release</span>&#8221;). A copy of the Pricing Press Release is furnished as Exhibit&#160;99.1 to this Current Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2 of Form <span style="white-space:nowrap">8-K,</span> the information furnished pursuant to this Item 7.01 and Exhibit&#160;99.1 shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information furnished pursuant to Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely to satisfy the requirements of Regulation FD. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512290dex11.htm">Underwriting Agreement, dated as of May&#160;31, 2023, by and among Lexicon Pharmaceuticals, Inc. and Citigroup Global Markets Inc., Jefferies LLC and Piper Sandler&#160;&amp; Co., as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512290dex51.htm">Opinion of Vinson&#160;&amp; Elkins L.L.P. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512290dex101.htm">Purchase Agreement, dated as of May&#160;31, 2023, among Lexicon Pharmaceuticals, Inc. and Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Mr.&#160;Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512290dex51.htm">Consent of Vinson&#160;&amp; Elkins L.L.P. (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512290dex991.htm">Pricing Press Release, dated June&#160;1, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"><span style="white-space:nowrap">EX-104</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signatures </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Lexicon Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;2, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian T. Crum</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Brian T. Crum</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Senior Vice President and General Counsel</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d512290dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23,924,705 Shares </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common Stock
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">($0.001 par value) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">May&nbsp;31,
2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">c/o</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Citigroup Global Markets Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>388 Greenwich Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>New York, New York 10013 </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c/o</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Jefferies LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>New York, New York 10022 </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">c/o</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Piper Sandler&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">800 Nicollet Mall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Minneapolis, Minnesota 55402</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the &#147;<U>Company</U>&#148;), proposes to sell to the
several underwriters named in <U>Schedule II</U> hereto (the &#147;<U>Underwriters</U>&#148;), for whom you (the &#147;<U>Representatives</U>&#148;) are acting as representatives, the number of shares of common stock, $0.001 par value
(&#147;<U>Common Stock</U>&#148;) of the Company set forth in <U>Schedule I</U> hereto (the &#147;<U>Shares</U>&#148;) (said Shares to be issued and sold by the Company being hereinafter called the &#147;<U>Underwritten Securities</U>&#148;). The
Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in <U>Schedule I</U> hereto (the &#147;<U>Option Securities</U>;&#148; the Option Securities, together with the
Underwritten Securities, being hereinafter called the &#147;<U>Securities</U>&#148;). To the extent there are no additional Underwriters listed on <U>Schedule II</U> other than you, the term Representatives as used herein shall mean you, as
Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this
underwriting agreement (this &#147;<U>Agreement</U>&#148;), the &#147;<U>Registration Statement</U>&#148; means the registration statement referred to in paragraph 1(a) hereof, including the exhibits, schedules and financial statements and any
prospectus supplement relating to the Securities that is filed with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder (the &#147;<U>Securities Act</U>&#148;) and deemed part of such registration statement pursuant to Rule </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
430B under the Securities Act, as amended on each Effective Date, and, in the event any post-effective amendment thereto or any registration statement and any amendments thereto filed pursuant to
Rule 462(b) under the Securities Act (a &#147;<U>Rule 462(b) Registration Statement</U>&#148;)<B> </B>becomes effective prior to the Closing Date (as defined in Section&nbsp;3 hereof), shall also mean such registration statement as so amended or
such Rule 462(b) Registration Statement, as the case may be; the &#147;<U>Effective Date</U>&#148; means each date and time that the Registration Statement, any post-effective amendment or amendments thereto or any Rule 462(b) Registration Statement
became or becomes effective; the &#147;<U>Base Prospectus</U>&#148; means the base prospectus referred to in paragraph 1(a) hereof contained in the Registration Statement at the date and time that this Agreement is executed and delivered by the
parties hereto (the &#147;<U>Execution Time</U>&#148;); the &#147;<U>Preliminary Prospectus Supplement</U>&#148; means any preliminary prospectus supplement to the Base Prospectus referred to in paragraph 1(a) hereof which is used prior to the
filing of the Final Prospectus Supplement, together with the Base Prospectus; and the &#147;<U>Final Prospectus Supplement</U>&#148; means the prospectus supplement relating to the Securities that is first filed pursuant to Rule 424(b) under the
Securities Act (&#147;<U>Rule 424(b)</U>&#148;) after the Execution Time, together with the Base Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference herein to the
Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> which were filed under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the &#147;<U>Exchange Act</U>&#148;) on or before the most recent Effective Date of
the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or
&#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange
Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the &#147;<U>Pricing Disclosure Package</U>&#148; shall mean (i)&nbsp;the Base Prospectus, (ii)&nbsp;the
Preliminary Prospectus Supplement used most recently prior to the Execution Time, (iii)&nbsp;any issuer free writing prospectus, as defined in Rule 433 under the Securities Act (an &#147;<U>Issuer Free Writing Prospectus</U>&#148;), identified in
<U>Schedule III</U> hereto, and (iv)&nbsp;any other free writing prospectus, as defined in Rule 405 under the Securities Act (a &#147;<U>Free Writing Prospectus</U>&#148;), that the parties hereto shall hereafter expressly agree in writing to treat
as part of the Pricing Disclosure Package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Representations and Warranties</U>. The Company represents and warrants to, and agrees
with, each Underwriter as set forth below in this Section&nbsp;1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act and has prepared and filed with the SEC a shelf registration statement, as defined in Rule 405 (file number <FONT STYLE="white-space:nowrap">333-258564)</FONT> on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> including a related Base Prospectus, for registration under the Securities Act of the offering and sale of the Shares. The Company may have filed one or more amendments thereto, including any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Preliminary Prospectus Supplement, each of which has previously been furnished to you and has become effective upon filing. The Company will next file with the SEC a Final Prospectus Supplement
relating to the Shares in accordance with Rule 424(b). As filed, such Final Prospectus Supplement shall be, except to the extent the Representatives shall agree in writing to a modification, in all substantive respects in the form furnished to you
prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain only such specific additional information and other changes (beyond that contained in the Base Prospectus and any Preliminary Prospectus Supplement) as
the Company has advised you, prior to the Execution Time, will be included or made therein. The Registration Statement, at the Execution Time, is effective and meets the requirements set forth in Rule 415(a)(1)(x). There is no order preventing or
suspending the use of the Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement, and, to the knowledge of the Company, no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against
the Company or related to the offering has been initiated or threatened by the SEC and no notice of objection of the SEC to the use of such Registration Statement pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company.
Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to
Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the
Final Prospectus Supplement, as the case may be; and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus
Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary
Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On each Effective Date, the Registration Statement did, and when the Final Prospectus Supplement is first filed in
accordance with Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (and any amendment or supplement thereto) will, comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act and the
respective rules thereunder; on each Effective Date, at the Execution Time, and on the Closing Date, the Registration Statement did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and on the date of any filing pursuant to Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (together with any amendment or supplement thereto) will not
include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that
the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Final Prospectus Supplement (or any amendment or supplement thereto) in reliance upon and in conformity with
information furnished in writing to the Company by the Underwriters specifically for inclusion in the Registration Statement or the Final Prospectus Supplement (or any amendment or supplement thereto), it being understood and agreed that the only
such information furnished by the Underwriters consists of the information described as such in Section&nbsp;8(b) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As of the Execution Time, the Pricing Disclosure Package, when taken
together as a whole with the pricing information set forth in <U>Schedule I</U> hereto does not, and as of the Closing Date will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from the Pricing Disclosure Package based upon and in conformity with written
information furnished to the Company by the Underwriters specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf of the Underwriters consists of the information described as such in
Section&nbsp;8(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;(i) At the earliest time after the filing of the Registration Statement that the
Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii)&nbsp;as of the Execution Time (with such date being used as the determination date for purposes of this clause (ii)),
the Company was not and is not an Ineligible Issuer (as defined in Rule 405), without taking account of any determination by the SEC pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) or will pay such fee within the time
period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any of the Shares by
means of any &#147;prospectus&#148; (within the meaning of the Securities Act) or used any &#147;prospectus&#148; (within the meaning of the Securities Act) in connection with the offer or sale of the Shares, in each case other than the Registration
Statement, any Preliminary Prospectus Supplement and the Final Prospectus Supplement. The Company represents and agrees that it has not and, unless it obtains the prior consent of the Underwriters, it will not make any offer relating to the Shares
that would constitute an &#147;Issuer Free Writing Prospectus&#148; or that would otherwise constitute a &#147;Free Writing Prospectus&#148; other than any Permitted Free Writing Prospectus. Any such Free Writing Prospectus relating to the Shares
consented to by the Representatives is hereinafter referred to as a &#147;<U>Permitted Free Writing Prospectus</U>.&#148; The Company has complied and will comply in all material respects with the requirements of Rule 433 under the Securities Act
applicable to any Permitted Free Writing Prospectus, including timely filing with the SEC where required, legending and record keeping. Each Permitted Free Writing Prospectus does not conflict with the information contained in the Registration
Statement or the Pricing Disclosure Package did not and on the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <I>provided, however</I>, that the Company makes no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
representations or warranties as to the information contained in or omitted from such Permitted Free Writing Prospectus in reliance upon and in conformity with information furnished in writing to
the Company by the Underwriters specifically for inclusion in such Permitted Free Writing Prospectus, it being understood and agreed that the only such information furnished by the Underwriters consists of the information described as such in
Section&nbsp;8(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All statistical, demographic and market-related data included in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent the Company&#146;s good
faith estimates that are made on the basis thereof. To the extent required, the Company has obtained the written consent for the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company has established and maintains &#147;disclosure controls and procedures&#148; (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is
made known to the Company&#146;s principal executive officer and its principal financial or accounting executive officer by others within those entities, within the time periods specified in the SEC&#146;s rules and forms; (ii)&nbsp;have been
evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of
the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over
financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;(i) The Company&#146;s authorized equity capitalization is as set forth in the Pricing Disclosure Package and the
Final Prospectus Supplement; (ii)&nbsp;the capital stock of the Company conforms in all material respects to the description thereof contained in the Pricing Disclosure Package and the Final Prospectus Supplement; (iii)&nbsp;the outstanding shares
of Common Stock have been duly and validly authorized and issued and are fully paid and nonassessable; (iv)&nbsp;the Shares have been duly and validly authorized and, when issued and delivered to and paid for by the Underwriters pursuant to this
Agreement, will be fully paid and nonassessable; (v)&nbsp;the holders of outstanding shares of capital stock of the Company are not entitled to preemptive or other rights to subscribe for the Securities, except for any such rights as have been
effectively waived or satisfied; and, (vi)&nbsp;except as set forth in the Pricing Disclosure Package and the Final Prospectus Supplement, no options, warrants or other rights to purchase, agreements or other obligations to issue, or rights to
convert any obligations into or exchange any securities for, shares of capital stock of or ownership interests in the Company are outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) There is no material agreement required to be described in the
Registration Statement or incorporated therein, or to be filed as an exhibit thereto, which is not described or filed as required (and the Preliminary Prospectus Supplement contains in all material respects the same description of the foregoing
matters contained in the Final Prospectus Supplement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Except as otherwise disclosed in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement, there are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering
contemplated by this Agreement, except for such rights as have been duly waived or satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Subsequent to the
respective dates as of which information is given in the Registration Statement and the Final Prospectus Supplement: (i)&nbsp;there has been no material adverse change, or any development that could be reasonably expected to result in a material
adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of
business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to
herein as a &#147;<U>Material Adverse Change</U>&#148;); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses
or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material,
individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the
capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to
the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in
this Agreement includes the related notes thereto) filed with the SEC as a part of the Registration Statement, the Base Prospectus and the Final Prospectus Supplement, is (i)&nbsp;an independent registered public accounting firm as required by the
Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<U>PCAOB</U>&#148;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT
STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked
and who has not requested such registration to be withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The financial statements filed with the SEC as a part of the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement comply as to form in all material respects with the requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and
present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the
periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes
thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement fairly presents the information called
for in all material respects and has been prepared in accordance with the SEC&#146;s rules and guidelines applicable thereto in all material respects. No other financial statements or supporting schedules are required to be included in the
Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) The Company and each of its
subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific
authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets;
(iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is
taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement fairly presents the information called for in all material respects and is prepared in accordance with the SEC&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement and to enter into and perform its obligations under this Agreement except to the extent that the failure to be in good standing or have such power or authority would not result in a Material Adverse Change. The Company is duly qualified
as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent
that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of
this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under
the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus Supplement except to the extent that the failure to be in good standing or have such power or authority would not result in a Material Adverse Change. Each of the Company&#146;s subsidiaries is duly
qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such
qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the
Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Final Prospectus Supplement, are owned by the Company, directly or through subsidiaries, free and
clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim (except for such liens granted under that certain loan and security agreement, dated as of March&nbsp;17, 2022 (as amended and modified to the date hereof), among
the Company, Lexicon Pharmaceuticals (New Jersey), Inc., Oxford Finance LLC, the lenders listed on Schedule 1.1 thereto and Oxford Finance Credit Fund III, LP (the &#147;<U>Loan and Security Agreement</U>&#148;). The Company does not own or control,
directly or indirectly, any corporation, association or other entity that would constitute a significant subsidiary as defined under Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> other
than the subsidiaries listed in Exhibit 21 to the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The Common Stock (including the Shares) conform in all material respects to the description thereof contained in the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. All of the issued and outstanding Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in
compliance with all federal and state securities laws. None of the outstanding Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.
There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or
any of its subsidiaries other than those described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) The Common Stock are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and are listed on the Nasdaq
Global Select Market (&#147;<U>Nasdaq</U>&#148;), and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from
Nasdaq, nor has the Company received any notification that the SEC or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance in all material respects with all applicable listing
requirements of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Neither the Company nor any of its subsidiaries is in violation of its
charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<U>Default</U>&#148;) under any
indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing,
securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not
be expected, individually or in the aggregate, to result in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Neither the issue and sale of
the Securities nor the consummation of any other of the transactions contemplated by this Agreement, nor the execution, delivery and performance of this Agreement by the Company, nor the fulfillment of the terms hereof will conflict with, result in
a breach or violation of, or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, (i)&nbsp;the charter or bylaws of the Company or any of its subsidiaries, (ii)&nbsp;the
terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or
their property is subject, or (iii)&nbsp;any statute, law, rule, regulation, judgment, order or decree applicable to the Company or any of its subsidiaries of any court, regulatory body, administrative agency, governmental body, arbitrator or other
authority having jurisdiction over the Company or any of its subsidiaries or any of its or their properties, except in the case of clauses (ii)&nbsp;and (iii) for any such breach, violation or imposition as would not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change and as would not materially adversely affect the ability of the Underwriters to consummate the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now
pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with
the employees of the Company exists, except as described in the Final Prospectus Supplement, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of
any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) The
Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus Supplement as being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
owned or licensed by them and which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively,
&#147;<U>Intellectual Property</U>&#148;) and, to the Company&#146;s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others. The Intellectual Property
owned by the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the
Company&#146;s knowledge: (i)&nbsp;except as otherwise disclosed in the Final Prospectus Supplement and with respect to LX9211 (to which the Company has acquired an exclusive license), there are no third parties who have ownership, royalty, or
exclusive license rights to any Intellectual Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus Supplement as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no material infringement by third parties of any Intellectual Property owned by the Company. There is no
pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property licensed to the Company; (B)&nbsp;challenging the validity,
enforceability or scope of any Intellectual Property owned by the Company; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in
the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other intellectual rights of
others. The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are, to the Company&#146;s
knowledge, in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to
protect, maintain and safeguard Intellectual Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to
the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any such agreement. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the
United States patents and patent applications included in the Intellectual Property owned by the Company have been materially complied with; and in all foreign offices having similar requirements, all such requirements have been materially complied
with. The product candidates described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents
or patent applications owned by, or exclusively licensed to, the Company or any subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) The Company and each subsidiary possess such valid and current
certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus Supplement (&#147;<U>Permits</U>&#148;), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or
modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) To the Company&#146;s knowledge, the manufacturing facilities and operations of its suppliers or its subsidiaries are
operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the of the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;) and comparable drug regulatory agencies outside of the United
States to which it is subject (collectively, the &#147;<U>Regulatory Authorities</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) The application of the
proceeds received by the Company from the issuance, sale and delivery of the Securities as described in the Pricing Disclosure Package and the Final Prospectus Supplement will not violate Regulation T, U or X of the Board of Governors of the Federal
Reserve system or any other regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) No consent, approval, authorization, filing with
or order of any court or governmental agency or body is required in connection with the transactions contemplated herein, except such as have been obtained under the Securities Act and such as may be required under the listing rules of the Nasdaq,
applicable rules of the Financial Industry Regulatory Authority, Inc. (&#147;<U>FINRA</U>&#148;) and the blue sky laws of any jurisdiction in connection with the purchase and distribution of the Securities by the Underwriters in the manner
contemplated herein and in the Pricing Disclosure Package and the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) Except as otherwise
disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets owned by them
which is material to the business of the Company, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects except as do not materially affect the value of such property and do
not interfere in any material respect with the use made and currently proposed to be made of such property by the Company. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries
are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such
subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material
Adverse Change, the Company and its subsidiaries (i)&nbsp;have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii)&nbsp;have paid all taxes required to be paid by any
of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in
accordance with generally accepted accounting principles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) There are no transfer taxes or other similar fees or charges under
federal law or the laws of any state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement, any other document to be furnished hereunder or the issuance by the Company or sale by
the Company of the Securities to the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company is not, and will not be, either after receipt of
payment for the Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, required to register as an
&#147;investment company&#148; under the Investment Company Act of 1940, as amended (the &#147;<U>Investment Company Act</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company and each of its subsidiaries is insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company and its subsidiaries are in compliance with the terms of such policies and instruments in all material respects; and there are no
material claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; neither the Company nor any such subsidiary has
been refused any insurance coverage sought or applied for; and neither the Company nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or obtain
similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement, no subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock, from repaying to the Company any loans or
advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s property or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that
reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Stock or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;<U>Regulation
M</U>&#148;)) with respect to the Common Stock, whether to facilitate the sale or resale of the Shares or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)
There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement which have not been described as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) Neither the Company nor any of its subsidiaries nor, to the best of the
Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character
required to be disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) Except as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement and
except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law
(including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative interpretation thereof, relating to pollution or protection of human health (to the extent relating to exposure to Hazardous
Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release of
pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by any governmental authority (collectively, &#147;<U>Hazardous Materials</U>&#148;) or to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<U>Environmental Laws</U>&#148;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of them under Environmental Laws for
their operations as currently conducted and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii)&nbsp;the Company and its subsidiaries have not received written notice of any pending or
threatened liability under any Environmental Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) Except as would not, individually or in the aggregate, result in a Material Adverse Change: (i)&nbsp;the Company and its
subsidiaries and any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<U>ERISA</U>&#148;))
established or maintained by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA; &#147;<U>ERISA Affiliate</U>&#148; means, with respect to the Company or any
of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
&#147;<U>Code</U>&#148;) of which the Company or such subsidiary is a member; (ii)&nbsp;no &#147;reportable event&#148; (as defined under ERISA), other than an event for which the <FONT STYLE="white-space:nowrap">30-day</FONT> notice period is
waived, has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates; (iii)&nbsp;no &#147;employee benefit
plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA); (iv) neither the Company, its subsidiaries nor any
of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (b)&nbsp;Sections 412, 4971, 4975 or
4980B of the Code; and (v)&nbsp;each &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified
and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) The Company and its subsidiaries are in compliance with all applicable laws, rules and regulations, except where failure
to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, or employee
of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or
any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or
authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party,
party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<U>FCPA</U>&#148;), the UK Bribery Act 2010, or any other applicable
anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its
subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are
reasonably expected to continue to ensure, continued compliance therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) The operations of the Company and its
subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all
applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<U>Money Laundering
Laws</U>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the
best knowledge of the Company, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) The preclinical tests and clinical trials, and other studies
(collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement were and, if still pending, are, to the
Company&#146;s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates
comparable to those being developed by the Company; the descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company
and its subsidiaries have no knowledge of any other studies the results of which reasonably call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement;
the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or
foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#147;<U>Regulatory Agencies</U>&#148;) except where failure to do so would not result in a Material Adverse
Change; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) The Company:
(A)&nbsp;is in compliance with the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.) and the regulations promulgated thereunder (the &#147;<U>FDCA</U>&#148;) except where failure to be so in compliance would not result in a
Material Adverse Change; (B)&nbsp;has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA alleging or asserting material noncompliance with the FDCA
or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required under the FDCA (&#147;<U>Authorizations</U>&#148;); (C) possesses all material Authorizations and such
Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations except where failure to possess or be so in compliance with such Authorizations would not reasonably be
expected to result in a Material Adverse Change; (D)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party
alleging that any product operation or activity is in material violation of the FDCA or the terms of any Authorization and has no knowledge that the FDA or any governmental entity or third party is considering any such claim, litigation,
arbitration, action, suit, investigation or proceeding, which if resolved adversely to the Company, would reasonably be expected to have a Material Adverse Change; (E)&nbsp;has not received written notice that the FDA or any governmental entity has
taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
knowledge that the FDA or any governmental entity is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required under the FDCA or any Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were
materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission), except where instances of failure to file, obtain, maintain or submit required documentation would not reasonably be expected to result
in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company,
directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<U>OFAC</U>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury of the United Kingdom, or other
relevant sanctions authority (collectively, &#147;<U>Sanctions</U>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without
limitation, Cuba, Iran, North Korea, Syria, and the Crimea, <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, and <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic regions of Ukraine and
the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of Zaporizhzhia and Kherson Regions (collectively, the &#147;<U>Sanctioned Countries</U>&#148;); and the Company will not directly or indirectly use the proceeds of this
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or
territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor,
investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing
or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) The Company and the
Company&#146;s directors or officers, in their capacities as such, are in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) The Company&#146;s and its subsidiaries&#146; information technology assets and equipment, computers, <FONT
STYLE="white-space:nowrap">on-premise</FONT> and remote systems, networks, hardware, and databases (collectively, &#147;<U>IT Systems</U>&#148;) are reasonably adequate for the operation of the business of the Company and its subsidiaries as
currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<U>Personal Data</U>&#148; means (i)&nbsp;a natural person&#146;s
name, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport
number, credit card number, or bank account information; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data,&#148;
&#147;personal information,&#148; or similar term as defined by CCPA (as defined below), CPRA (as defined below), GDPR (as defined below) or any other applicable Privacy Laws; (iv)&nbsp;any information which would qualify as &#147;protected health
information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<U>HIPAA</U>&#148;); and (v)&nbsp;any other piece of
information that, either alone or in combination with another piece of information, allows for the identification of such natural person, his or her family or household, or a device, or permits the collection or analysis of any data related to an
identified person&#146;s health or sexual orientation, and together with all proprietary or confidential information of the Company, &#147;Sensitive Data.&#148; In the past three years, there have been no breaches, violations, outages or
unauthorized uses of or accesses to such Sensitive Data or IT Systems, except for those that have been remedied without material cost or liability or the duty to notify any other person or governmental authority under Privacy Laws (as defined
below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable
foreign, state and federal data privacy and security laws and regulations, including without limitation HIPAA, the European Union General Data Protection Regulation (&#147;<U>EU GDPR</U>&#148;) (EU 2016/679) and the United Kingdom General Data
Protection Regulation (&#147;UK GDPR&#148;), and all state privacy laws (including the California Consumer Privacy Act (&#147;CCPA&#148;), California Privacy Rights Act (&#147;CPRA&#148;) and similar laws in any other states) (collectively, the
&#147;<U>Privacy Laws</U>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps to ensure compliance in all material respects with the Company&#146;s internal and
external policies and procedures relating to data privacy and security and the collection, processing, storage, use, disclosure, handling, transfer and analysis of Sensitive Data (the &#147;<U>Policies</U>&#148;). The Company further certifies that
neither it nor any subsidiary: (i)&nbsp;has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or
in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or settlement agreement issued by a governmental authority that
imposes any obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) The Company (i)&nbsp;does not have any material lending or
other relationship with any bank or lending affiliate of the Underwriters and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate of the Underwriters.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) The Company and its subsidiaries are, and at all times have been, in
compliance with all applicable Health Care Laws, except to the extent that any <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. For
purposes of this Agreement, &#147;<U>Health Care Laws</U>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations
promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18
U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act
(42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under
applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the
directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care
Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the aggregate, reasonably be
expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as
required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or
supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any
governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from
participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to
result in debarment, suspension, or exclusion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) The statements contained in the Preliminary Prospectus Supplement and
the Final Prospectus Supplement under the captions &#147;Business&#151;Patents and Proprietary Rights,&#148; &#147;Business&#151;Government Regulation,&#148; &#147;Risk Factors&#151;Risks Related to Our Intellectual Property,&#148; insofar as such
statements summarize legal matters, agreements, documents, or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements, documents or proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) Any certificate signed by any officer of the Company and delivered to
the Underwriters or counsel for the Underwriters in connection with the offering of the Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Underwriters, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) contained in either the Pricing Disclosure Package or the Final Prospectus Supplement has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Company
agrees to sell to each Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company, at the purchase price set forth in <U>Schedule I</U> hereto, the number of Underwritten Securities set forth opposite such
Underwriter&#146;s name in <U>Schedule</U><U></U><U>&nbsp;II</U> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and conditions and in
reliance upon the representations and warranties herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to the number of Option Securities set forth in <U>Schedule I</U> hereto at
the same purchase price per share as the Underwriters shall pay for the Underwritten Securities, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Securities but not payable on
the Option Securities. Said option may be exercised in whole or in part at any time on or before the 30th day after the date of the Final Prospectus Supplement upon written or telegraphic notice by the Representatives to the Company setting forth
the number of Option Securities as to which the several Underwriters are exercising the option and the settlement date. The number of Option Securities to be purchased by each Underwriter shall be the same percentage of the total number of Option
Securities to be purchased by the several Underwriters as such Underwriter is purchasing of the Underwritten Securities, subject to such adjustments as you in your absolute discretion shall make to eliminate any fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Delivery and Payment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Delivery of and payment for the Underwritten Securities and the Option Securities (if the option provided for in
Section&nbsp;2(b) hereof shall have been exercised on or before the first Business Day immediately preceding the Closing Date) shall be made on the date and at the time specified in <U>Schedule I</U> hereto or at such time on such later date not
more than two Business Days after the foregoing date as the Representatives shall designate, which date and time may be postponed by agreement between the Representatives and the Company or as provided in Section&nbsp;9 hereof (such date and time of
delivery and payment for the Securities being herein called the &#147;<U>Closing Date</U>&#148;). As </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
used herein, &#147;Business Day&#148; shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated
by law to close in New York City. Delivery of the Securities shall be made to the Representatives for the respective accounts of the several Underwriters against payment by the several Underwriters through the Representatives of the purchase price
thereof to or upon the order of the Company by wire transfer payable in <FONT STYLE="white-space:nowrap">same-day</FONT> funds to an account specified by the Company. Delivery of the Underwritten Securities (other than the Warrants) and the Option
Securities shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the option provided for in Section&nbsp;2(b) hereof is exercised after the third Business Day immediately preceding the
Closing Date, the Company will deliver the Option Securities (at the expense of the Company) to the Representatives, at 388 Greenwich Street, New York, New York, on the date specified by the Representatives (which shall be within three Business Days
after exercise of said option) for the respective accounts of the several Underwriters, against payment by the several Underwriters through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer
payable in <FONT STYLE="white-space:nowrap">same-day</FONT> funds to an account specified by the Company. If settlement for the Option Securities occurs after the Closing Date, the Company will deliver to the Representatives on the settlement date
for the Option Securities, and the obligation of the Underwriters to purchase the Option Securities shall be conditioned upon receipt of, supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and
letters delivered on the Closing Date pursuant to Section&nbsp;6 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Offering by Underwriters</U>. It is understood that the
several Underwriters propose to offer the Securities for sale to the public as set forth in the Final Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Agreements</U>. The Company agrees with the several Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the termination of the offering of
the Securities, the Company will not file any amendment of the Registration Statement or supplement (including the Final Prospectus Supplement or any Preliminary Prospectus Supplement) to the Base Prospectus or any Rule&nbsp;462(b) Registration
Statement unless the Company has furnished you a copy for your review prior to filing and will not file any such proposed amendment or supplement to which you reasonably object. The Company will cause the Final Prospectus Supplement, properly
completed, and any supplement thereto to be filed in a form approved (such approval not to be unreasonably withheld) by the Representatives with the SEC pursuant to the applicable paragraph of Rule&nbsp;424(b) within the time period prescribed and
will provide evidence satisfactory to the Representatives of such timely filing. The Company will promptly advise the Representatives (i)&nbsp;when the Final Prospectus Supplement, and any supplement thereto, shall have been filed (if required) with
the SEC pursuant to Rule&nbsp;424(b) or when any Rule&nbsp;462(b) Registration Statement shall have been filed with the SEC, (ii)&nbsp;when, prior to termination of the offering of the Securities, any amendment to the Registration Statement shall
have been filed or become effective, (iii)&nbsp;of any request by the SEC or its staff for any amendment of the Registration Statement, or any Rule&nbsp;462(b) Registration Statement, or for any supplement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to the Final Prospectus Supplement or for any additional information, (iv)&nbsp;of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or of any
notice objecting to its use or the institution or threatening of any proceeding for that purpose and (v)&nbsp;of the receipt by the Company of any notification with respect to the suspension of the qualification of the Securities for sale in any
jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its best efforts to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the
Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief from such occurrence or objection, including, if necessary, by filing an amendment to the
Registration Statement or a new registration statement and using its best efforts to have such amendment or new registration statement declared effective as soon as practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, at any time prior to the filing of the Final Prospectus Supplement pursuant to Rule 424(b), any event occurs as a
result of which the Pricing Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or
the circumstances then prevailing not misleading, the Company will (i)&nbsp;notify promptly the Representatives so that any use of the Pricing Disclosure Package may cease until it is amended or supplemented; (ii)&nbsp;amend or supplement the
Pricing Disclosure Package to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to you in such quantities as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, at any time when a prospectus relating to the Securities is required to be delivered under the Securities Act
(including in circumstances where such requirement may be satisfied pursuant to Rule 172), any event occurs as a result of which the Final Prospectus Supplement as then supplemented would include any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, or if it shall be necessary to amend the Registration
Statement, file a new registration statement or supplement the Final Prospectus Supplement to comply with the Securities Act or the Exchange Act or the respective rules thereunder, including in connection with use or delivery of the Final Prospectus
Supplement, the Company promptly will (i)&nbsp;notify the Representatives of any such event, (ii)&nbsp;prepare and file with the SEC, subject to the second sentence of paragraph (a)&nbsp;of this Section&nbsp;5, an amendment or supplement or new
registration statement which will correct such statement or omission or effect such compliance, (iii)&nbsp;use its best efforts to have any amendment to the Registration Statement or new registration statement declared effective as soon as
reasonably practicable in order to avoid any disruption in use of the Final Prospectus Supplement and (iv)&nbsp;supply any supplemented Final Prospectus Supplement to you in such quantities as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) As soon as reasonably practicable, the Company will make generally available to its security holders and to the
Representatives an earnings statement or statements of the Company and its subsidiaries which will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company will furnish to the Representatives and counsel for the
Underwriters, without charge, signed copies of the Registration Statement (including exhibits thereto) and to each other Underwriter a copy of the Registration Statement (without exhibits thereto) and, so long as delivery of a prospectus by an
Underwriter or dealer may be required by the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172), as many copies of each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each
Issuer Free Writing Prospectus and any supplement thereto as the Representatives may reasonably request. The Company will pay the expenses of printing or other production of all documents relating to the offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company will cooperate with the Representatives to arrange, if reasonably necessary, for the qualification of the
Securities for sale under the laws of such jurisdictions as the Representatives may designate and will maintain such qualifications in effect so long as required for the distribution of the Securities; <I>provided</I> that in no event shall the
Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Securities,
in any jurisdiction where it is not now so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company will not, without the prior written consent of the
Representatives, offer, sell, contract to sell, pledge, hedge, or otherwise dispose of, (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective
economic disposition due to cash settlement or otherwise) by the Company&nbsp;or any affiliate of the Company or any person in privity with the Company or any affiliate of the Company) directly or indirectly, including the submission or filing (or
participation in the submission or filing) of a registration statement with the SEC in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section&nbsp;16 of the
Exchange Act, any other shares of Common Stock or any securities convertible into, or exercisable, or exchangeable for, shares of Common Stock; or publicly announce an intention to effect any such transaction, for a period of 60 days after the date
of this Agreement (such period, the &#147;<U>Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</U>&#148;), <I>provided</I>, <I>however</I>, that the Company may: (i)&nbsp;effect the transactions contemplated hereby and issue shares of
Common Stock pursuant to the potential concurrent private placement described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement; (ii)&nbsp;issue warrants to purchase shares of Common Stock with a value
equal to up to $656,250, pursuant to an election to obtain a Term C Loan within 60 days upon the FDA&#146;s approval of INPEFA pursuant to the Loan and Security Agreement, provided that if any filing under Section&nbsp;16(a) of the Exchange Act
shall be legally required during the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (iii)&nbsp;grant
options, restricted stock units or other equity awards or issue shares of Common Stock to its employees, officers, directors, advisors or consultants pursuant to employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
benefit plans of the Company, <I>provided</I>, that each recipient of such securities that is a newly appointed director or executive officer pursuant to this clause (iii)&nbsp;agree to
restrictions on the resale of securities that are consistent with the provisions set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;6(l) hereof; (iv)&nbsp;file one or more registration statements on
Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to stock options or employee benefit plans of the Company, and <I>provided</I>, <I>further</I>, that each recipient of such securities that is a newly appointed director or executive officer
agrees to restrictions on the resale of securities that are consistent with the provisions set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;6(l) hereof and (v)&nbsp;entering into any acquisition,
merger, consolidation, stock exchange or similar transaction whereby all or substantially all of the Common Stock is acquired by a third party, which is approved by the Board of Directors of the Company; <I>provided</I> that (A)&nbsp;any such
transaction is not solicited by the Company and (B)&nbsp;in the event the acquisition, merger, consolidation, stock exchange or other similar transaction is not completed, the Company shall remain subject to the restrictions contained herein. The
Company will provide the Representatives and each individual subject to the restricted period pursuant to the <FONT STYLE="white-space:nowrap">lock-up</FONT> letters described in Section&nbsp;6(l) hereof with prior notice of any such announcement
that gives rise to an extension of the restricted period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company will use its commercially reasonable efforts to
maintain the listing of the Shares issued and sold by the Company on the Nasdaq Global Select Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company will
not take, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company agrees to pay the costs and expenses relating
to the following matters: (i)&nbsp;the preparation, printing or reproduction and filing with the SEC of the Registration Statement (including financial statements and exhibits thereto), each Preliminary Prospectus Supplement, the Final Prospectus
Supplement and each Issuer Free Writing Prospectus, and each amendment or supplement to any of them; (ii)&nbsp;the printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies
of the Registration Statement, each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each Issuer Free Writing Prospectus, and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use
in connection with the offering and sale of the Securities; (iii)&nbsp;the preparation, printing, authentication, issuance and delivery of certificates for the Securities, including any stamp or transfer taxes in connection with the original
issuance and sale of the Securities to the Underwriters; (iv)&nbsp;the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with
the offering of the Securities; (v)&nbsp;the registration of the Securities under the Exchange Act and the listing of the Securities on Nasdaq; (vi)&nbsp;any registration or qualification of the Securities for offer and sale under the securities or
blue sky laws of the several states (including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such registration and qualification); (vii)&nbsp;FINRA (including
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such filings); (viii)&nbsp;the transportation and other expenses incurred by or on behalf of Company
representatives in connection with presentations to prospective purchasers of the Securities; (ix)&nbsp;the fees and expenses of the Company&#146;s accountants and the fees and expenses of counsel (including local and special counsel) for the
Company; and (x)&nbsp;all other costs and expenses incident to the performance by the Company of its obligations hereunder, <I>provided</I>, <I>however</I>, that the reasonable fees and expenses of counsel for the Underwriters incurred pursuant to
clauses (vi)&nbsp;and (vii) of this Section&nbsp;5(j) shall not exceed $20,000 in the aggregate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company agrees
that, unless it has or shall have obtained the prior written consent of the Representatives, and each Underwriter, severally and not jointly, agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written
consent of the Company, it has not made and will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company
with the SEC or retained by the Company under Rule 433 under the Securities Act (&#147;<U>Rule 433</U>&#148;); <I>provided</I> that the prior written consent of the parties hereto shall be deemed to have been given in respect of the Free Writing
Prospectuses included in <U>Schedule III</U> hereto and any electronic road show. The Company agrees that (x)&nbsp;it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and
(y)&nbsp;it has complied and will comply, as the case may be, with the requirements of Rule 164 under the Securities Act (&#147;<U>Rule 164</U>&#148;) and Rule 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely
filing with the SEC, legending and record keeping. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions to the Obligations of the Underwriters</U>. The obligations of the
Underwriters to purchase the Underwritten Securities and the Option Securities, as the case may be, shall be subject to the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, the
Closing Date and any settlement date pursuant to Section&nbsp;3 hereof, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and
to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Final Prospectus Supplement, and any supplement thereto, have been filed
in the manner and within the time period required by Rule&nbsp;424(b); any material required to be filed by the Company pursuant to Rule 433(d) shall have been filed with the SEC within the applicable time periods prescribed for such filings by Rule
433; and no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use shall have been issued and no proceedings for that purpose shall have been instituted or threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall have requested and caused Brian T. Crum, Senior Vice President and General Counsel of the Company, to
have furnished to the Representatives an opinion, dated the Closing Date and addressed to the Representatives, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall have requested and caused Max Bachrach, Ph.D.,
intellectual property counsel for the Company, to have furnished to the Representatives an opinion with respect to intellectual property matters, dated the Closing Date and addressed to the Representatives, in form and substance reasonably
satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company shall have requested and caused Vinson&nbsp;&amp; Elkins L.L.P.,
counsel for the Company, to have furnished to the Representatives their opinion and negative assurance letter, dated the Closing Date and addressed to the Representatives, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Representatives shall have received from Cooley LLP, counsel for the Underwriters, such opinion or opinions and
negative assurance letter, dated the Closing Date and addressed to the Representatives, with respect to the issuance and sale of the Securities, the Registration Statement, the Pricing Disclosure Package, the Final Prospectus Supplement (together
with any supplement thereto) and other related matters as the Representatives may reasonably require, and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company shall have furnished to the Representatives a certificate of the Company, signed by the Chief Executive
Officer or other principal executive officer of the Company, dated the Closing Date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the Pricing Disclosure Package, the Final Prospectus
Supplement and any amendments or supplements thereto, as well as each electronic road show used in connection with the offering of the Securities, and this Agreement and that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the representations and warranties of the Company in this Agreement are true and correct on and as of the Closing Date with
the same effect as if made on the Closing Date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use has been
issued and no proceedings for that purpose have been instituted or, to the Company&#146;s knowledge, threatened; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)
since the date of the most recent financial statements included or incorporated by reference in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto), there has been no Material Adverse
Change in the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in
or contemplated in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company shall have requested and caused Ernst&nbsp;&amp; Young LLP
to have furnished to the Representatives, at the Execution Time and at the Closing Date, letters (which may refer to letters previously delivered to one or more of the Representatives), dated respectively as of the Execution Time and as of the
Closing Date, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountants &#147;comfort letters&#148; to underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Subsequent to the Execution Time or, if earlier, the dates as of which information is given in the Registration Statement
(exclusive of any amendment thereof) and the Final Prospectus Supplement (exclusive of any supplement thereto), there shall not have been (i)&nbsp;any change or decrease specified in the letter or letters referred to in paragraph&nbsp;(e) of this
Section&nbsp;6 or (ii)&nbsp;any change, or any development involving a prospective change, in or affecting the condition (financial or otherwise), earnings, business or properties of the Company and its subsidiaries taken as a whole, whether or not
arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto) the effect of which, in any
case referred to in clause&nbsp;(i) or (ii)&nbsp;above, is, in the sole judgment of the Representatives, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by
the Registration Statement (exclusive of any amendment thereof), the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Prior to the Closing Date, the Company shall have furnished to the Representatives such further information, certificates
and documents as the Representatives may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Subsequent to the Execution Time, there shall not have
been any decrease in the rating of any of the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization&#148; (as defined for purposes of Rule 3(a)(62) under the Exchange Act) or any notice given of any
intended or potential decrease in any such rating or of a possible change in any such rating that does not indicate the direction of the possible change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Securities shall have been listed and admitted and authorized for trading on Nasdaq, and reasonably satisfactory
evidence of such actions shall have been provided to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) At the Execution Time, the Company shall
have furnished to the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter substantially in the form of <U>Exhibit A</U> hereto from each executive officer and director of the Company and the stockholders of the Company set forth
on <U>Exhibit B</U> addressed to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the conditions specified in this Section&nbsp;6 shall not have been fulfilled when
and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters, this
Agreement and all obligations of the Underwriters hereunder may be canceled at, or at any time prior to, the Closing Date by the Representatives. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile
confirmed in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents required to be delivered by this Section&nbsp;6 shall be delivered electronically to Cooley LLP,
counsel for the Underwriters, on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Reimbursement of Underwriters&#146; Expenses</U>. If the sale of the Securities
provided for herein is not consummated because any condition to the obligations of the Underwriters set forth in Section&nbsp;6 hereof is not satisfied, because of any termination pursuant to Section&nbsp;10(i) hereof or because of any refusal,
inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof other than by reason of a default by any of the Underwriters, the Company will reimburse the Underwriters severally through Citigroup
Global Markets Inc. on demand for all expenses (including reasonable and documented fees and disbursements of counsel) that shall have been incurred by them in connection with the proposed purchase and sale of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Underwriter, the directors, officers, employees, affiliates and
agents of each Underwriter and each person who controls any Underwriter within the meaning of either the Securities Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them
may become subject under the Securities Act, the Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Securities as originally filed or in any amendment thereof, or included in the Base Prospectus,
any Preliminary Prospectus Supplement, the Final Prospectus Supplement, or any Issuer Free Writing Prospectus or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, and agrees to reimburse each such indemnified party, as incurred, for any documented legal or other expenses reasonably incurred by them in
connection with investigating or defending any such loss, claim, damage, liability or action; <I>provided</I>, <I>however</I>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises
out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of any Underwriter
through the Representatives specifically for inclusion therein. This indemnity agreement will be in addition to any liability which the Company may otherwise have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter severally and not jointly agrees to indemnify and hold
harmless the Company, each of its directors, each of its officers who signs the Registration Statement, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, to the same extent as the foregoing
indemnity from the Company to each Underwriter, but only with reference to written information relating to such Underwriter furnished to the Company by or on behalf of such Underwriter through the Representatives specifically for inclusion in the
documents referred to in the foregoing indemnity. This indemnity agreement will be in addition to any liability which any Underwriter may otherwise have. The Company acknowledges that the statements set forth (i) in the last paragraph of the cover
page regarding delivery of the Securities and, under the heading &#147;Underwriting&#148; (ii)&nbsp;the list of Underwriters and their respective participation in the sale of the Securities, (iii)&nbsp;the sentences related to concessions and
reallowances and (iv)&nbsp;the paragraphs related to stabilization, syndicate covering transactions and penalty bids in any Preliminary Prospectus Supplement and the Final Prospectus Supplement constitute the only information furnished in writing by
or on behalf of the several Underwriters for inclusion in any Preliminary Prospectus Supplement, the Final Prospectus Supplement or any Issuer Free Writing Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this Section&nbsp;8 of notice of the commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;8, notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party
(i)&nbsp;will not relieve it from liability under paragraph&nbsp;(a) or&nbsp;(b) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the indemnifying party of substantial rights and
defenses and (ii)&nbsp;will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided in paragraph&nbsp;(a) or (b)&nbsp;above. The indemnifying party shall be
entitled to appoint counsel of the indemnifying party&#146;s choice at the indemnifying party&#146;s expense to represent the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall not
thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as set forth below); <I>provided</I>, <I>however</I>, that such counsel shall be satisfactory to the indemnified party.
Notwithstanding the indemnifying party&#146;s election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party
shall bear the reasonable fees, costs and expenses of such separate counsel if (i)&nbsp;the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii)&nbsp;the
actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other
indemnified parties which are different from or additional to those available to the indemnifying party, (iii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of the institution of such action or (iv)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written consent of
the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or
not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such claim,
action, suit or proceeding and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the event that the indemnity provided in paragraph&nbsp;(a), (b) or (c)&nbsp;of this Section&nbsp;8 is unavailable to or
insufficient to hold harmless an indemnified party for any reason, the Company and the Underwriters severally agree to contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in
connection with investigating or defending the same) (collectively, &#147;<U>Losses</U>&#148;) to which the Company and one or more of the Underwriters may be subject in such proportion as is appropriate to reflect the relative benefits received by
the Company on the one hand and by the Underwriters on the other from the offering of the Securities. If the allocation provided by the immediately preceding sentence is unavailable for any reason, the Company and the Underwriters severally shall
contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and of the Underwriters on the other in connection with the statements or omissions which resulted
in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by it, and benefits received by the
Underwriters shall be deemed to be equal to the total underwriting discounts and commissions, in each case as set forth on the cover page of the Final Prospectus Supplement. Relative fault shall be determined by reference to, among other things,
whether any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information provided by the Company on the one hand or the Underwriters on the other, the intent of the
parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contribution were determined by
pro rata allocation or any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph (d), in no event shall an Underwriter be required to contribute any
amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this paragraph&nbsp;(d), no person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;8, each person who controls an Underwriter within the meaning of either the Securities Act
or the Exchange Act and each director, officer, employee, affiliate and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
agent of an Underwriter shall have the same rights to contribution as such Underwriter, and each person who controls the Company within the meaning of either the Securities Act or the Exchange
Act, each officer of the Company who shall have signed the Registration Statement and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions of this
paragraph&nbsp;(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Default by an Underwriter</U>. If any one or more Underwriters shall fail to purchase and pay for any of the
Securities agreed to be purchased by such Underwriter or Underwriters hereunder and such failure to purchase shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Underwriters shall be
obligated severally to take up and pay for (in the respective proportions which the amount of Securities set forth opposite their names in <U>Schedule</U><U></U><U>&nbsp;II</U> hereto bears to the aggregate amount of Securities set forth opposite
the names of all the remaining Underwriters) the Securities which the defaulting Underwriter or Underwriters agreed but failed to purchase; <I>provided</I>, <I>however</I>, that in the event that the aggregate amount of Securities which the
defaulting Underwriter or Underwriters agreed but failed to purchase shall exceed 10% of the aggregate amount of Securities set forth in <U>Schedule</U><U></U><U>&nbsp;II</U> hereto, the remaining Underwriters shall have the right to purchase all,
but shall not be under any obligation to purchase any, of the Securities, and if such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not purchase all the Securities, this Agreement will terminate without liability to any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company. In the event of a default by any Underwriter as set forth in this Section&nbsp;9, the Closing Date shall be postponed for such period, not exceeding five Business Days, as
the Representatives shall determine in order that the required changes in the Registration Statement and the Final Prospectus Supplement or in any other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve any
defaulting Underwriter of its liability, if any, to the Company and any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages occasioned by its default hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Termination</U>. This Agreement shall be subject to termination in the absolute discretion of the Representatives, by notice given to
the Company prior to delivery of and payment for the Securities, if at any time prior to such delivery and payment (i)&nbsp;trading in the Company&#146;s Common Stock shall have been suspended by the SEC or Nasdaq or trading in securities generally
on the New York Stock Exchange or Nasdaq shall have been suspended or limited or minimum prices shall have been established on either of such exchanges, (ii)&nbsp;a banking moratorium shall have been declared either by Federal or New York State
authorities, (iii)&nbsp;there shall have occurred a material disruption in commercial banking or securities settlement or clearance services or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities, declaration by the United
States of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Representatives, impractical or inadvisable to proceed with the offering or delivery of
the Securities as contemplated by any Preliminary Prospectus Supplement or the Final Prospectus Supplement (exclusive of any amendment or supplement thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Representations and Indemnities to Survive</U>. The respective agreements, representations, warranties, indemnities and other
statements of the Company or its officers and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of
the officers, directors, employees, agents, affiliates or controlling persons referred to in Section&nbsp;8 hereof, and will survive delivery of and payment for the Securities. The provisions of Sections&nbsp;7 and 8 hereof shall survive the
termination or cancellation of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. All communications hereunder will be in writing and effective only on
receipt, and, if sent to the Representatives, will be mailed, delivered, telefaxed to c/o Citigroup Global Markets Inc. at 388 Greenwich Street, New York, New York 10013, Attention: General Counsel, facsimile number: +1 (646) <FONT
STYLE="white-space:nowrap">291-1469;</FONT> Jefferies LLC at 520 Madison Avenue, New York, New York 10022, Attention: General Counsel, facsimile number: +1 (646) <FONT STYLE="white-space:nowrap">619-4437;</FONT> and Piper Sandler&nbsp;&amp; Co. at
800 Nicollet Mall, Minneapolis, Minnesota 55402, Attention: General Counsel, LegalCapMarkets@psc.com; or, if sent to Lexicon Pharmaceuticals, Inc., will be mailed, delivered or telefaxed to 2445 Technology Forest Blvd., 11<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, The Woodlands, Texas 77381, Attention: General Counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Successors</U>.
This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons referred to in Section&nbsp;8 hereof, and no other person will
have any right or obligation hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Jurisdiction</U>. The Company agrees that any suit, action or proceeding against the
Company brought by any Underwriter, the directors, officers, employees, affiliates and agents of any Underwriter, or by any person who controls any Underwriter, arising out of or based upon this Agreement or the transactions contemplated hereby may
be instituted in any State or U.S. federal court in The City of New York and County of New York, and waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any suit, action or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Recognition of the
U.S. Special Resolution Regimes</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a
proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;15, &#147;<U>BHC Act Affiliate</U>&#148; has the meaning
assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); &#147;<U>Covered Entity</U>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &#167;&nbsp;252.82(b), (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;47.3(b) or (iii)&nbsp;a &#147;covered FSI&#148; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;382.2(b); &#147;<U>Default Right</U>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as
applicable; and &#147;<U>U.S. Special Resolution Regime</U>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection
Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>No Fiduciary Duty</U>. The Company hereby acknowledges that (a)&nbsp;the purchase
and sale of the Securities pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the Underwriters and any affiliate through which it may be acting,
on the other, (b)&nbsp;the Underwriters are acting as principal and not as an agent or fiduciary of the Company and (c)&nbsp;the Company&#146;s engagement of the Underwriters in connection with the offering and the process leading up to the offering
is as independent contractors and not in any other capacity. Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective of whether any of the Underwriters has advised or
is currently advising the Company on related or other matters). The Company agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in
connection with such transaction or the process leading thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Integration</U>. This Agreement supersedes all prior agreements
and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Applicable Law</U>. This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to
contracts made and to be performed within the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Waiver of Jury Trial</U>. The Company hereby irrevocably waives,
to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Counterparts</U>. This Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which
together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Headings</U>. The section headings used herein are for convenience only and shall not affect the construction hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall represent a binding agreement among the Company and the several Underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEXICON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Financial Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Underwriting Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The foregoing Agreement is hereby confirmed and accepted as of the date specified in <U>Schedule I</U> hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITIGROUP GLOBAL MARKETS INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PIPER SANDLER&nbsp;&amp; CO.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITIGROUP GLOBAL MARKETS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Brock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Brock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dustin Tyner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dustin Tyner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PIPER SANDLER&nbsp;&amp; CO.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Bassett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Bassett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For themselves and the other several</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Underwriters named in <U>Schedule II</U> to the foregoing Agreement.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Underwriting Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE&nbsp;I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriting Agreement, dated May&nbsp;31, 2023 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registration
Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-258564</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representatives: Citigroup Global Markets Inc., Jefferies LLC and Piper
Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title, Purchase Price and Description of Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Title: Common Stock, par value $0.001 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Underwritten Securities to be sold by the Company: 23,924,705 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Option Securities to be sold by the Company: 3,588,705 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Price per Share to Public (include accrued dividends, if any): $2.60 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Price per Share to the Underwriters &#150; total: $2.444 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Other provisions: None. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Closing Date, Time and
Location: June&nbsp;5, 2023 at 10:00 a.m., New York City time, at Cooley LLP, 3 Embarcadero Center, 20th&nbsp;Floor, San Francisco, California 94111 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Type
of Offering: <FONT STYLE="white-space:nowrap">Non-Delayed</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE&nbsp;II </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Underwritten<BR>Securities&nbsp;to&nbsp;be&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,373,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,373,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,177,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,924,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE&nbsp;III </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule of Free Writing Prospectuses included in the Pricing Disclosure Package </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Press Release, dated May&nbsp;31, 2023, titled &#147;Lexicon Announces Proposed Public Offering of Common
Stock&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">___________________, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global
Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Citigroup Global Markets Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10013 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jefferies LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10022 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Piper Sandler&nbsp;&amp; Co. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Minneapolis,
Minnesota 55402 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned understands that Citigroup Global Markets Inc. (&#147;<U>Citigroup</U>&#148;), Jefferies LLC (&#147;<U>Jefferies</U>&#148;) and Piper Sandler&nbsp;&amp; Co. (together with Citigroup and Jefferies, the &#147;<U>Representatives</U>&#148;)
propose to enter into an Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;) with Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), providing for the public offering (the
&#147;<U>Offering</U>&#148;) by the several Underwriters listed in Schedule II to the Underwriting Agreement (the &#147;<U>Underwriters</U>&#148;) of shares (the &#147;<U>Shares</U>&#148;) of the common stock, par value $0.001 per share, of the
Company (the &#147;<U>Common Stock</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce the Underwriters that may participate in the Offering to continue their efforts
in furtherance thereof, the undersigned hereby agrees not to, during the period commencing on the date hereof and ending 60 days after the date of the final prospectus supplement relating to the Offering (the &#147;<U>Prospectus</U>&#148;) (such
period, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#148;), without the prior written consent of the Representatives, (1)&nbsp;offer, pledge, hedge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a)&nbsp;transactions relating to shares of Common Stock or other securities acquired in
open market transactions after the completion of the Offering, <I>provided</I> that no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other
securities acquired in such open market transactions, (b)&nbsp;any surrender of shares of Common Stock (or options to purchase shares of Common Stock) to the Company by the undersigned in satisfaction of (i)&nbsp;any federal, state or local taxes
required by law to be withheld with respect to the vesting of shares of Common Stock or the exercise of stock options to purchase Common Stock and/or (ii)&nbsp;the exercise price payable to the Company with respect to the exercise of stock options
to purchase Common Stock, in each case granted under a stock incentive plan or stock purchase plan of the Company described in the Prospectus or any document incorporated by reference therein and in accordance with the terms of any such instrument
as in effect on or before the date hereof, (c)&nbsp;transfers of shares of Common Stock or any security convertible into Common Stock as a bona fide gift, (d)&nbsp;distributions of shares of Common Stock or any security convertible into Common Stock
to limited partners, members, stockholders or equityholders of the undersigned, (e)&nbsp;transfers to immediate family of the undersigned, to a trust all of the beneficiaries of which are the undersigned and/or members of his or her immediate family
or to a corporation, partnership, limited partnership or limited liability company all of the stockholders, partners and members of which are the undersigned and/or members of his or her immediate family, in each case for estate planning purposes,
(f)&nbsp;transfers by will or other testamentary document, or intestacy; <I>provided</I> that (i)&nbsp;in the case of any transfer or distribution pursuant to clauses (c) &#150; (f) each donee, distributee or transferee shall sign and deliver a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of this agreement and (ii)&nbsp;in the case of any surrender, transfer or distribution pursuant to clauses (b) &#150; (f), no filing under Section&nbsp;16(a) of the
Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, (g)&nbsp;any transfers, surrenders or
distributions, or offers to take any such action, in connection with a bona fide third party takeover bid made to all or substantially all holders of Common Stock or any other acquisition, merger, consolidation, stock exchange or other similar
transaction whereby all or substantially all of the Common Stock is acquired by a third party; <I>provided</I> that in the event the third party takeover bid or other acquisition, merger, consolidation, stock exchange or other similar transaction is
not completed, the undersigned shall remain subject to the restrictions contained here herein, (h)&nbsp;the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of
shares of Common Stock; <I>provided</I> that such plan does not provide for the transfer of Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, except as otherwise permitted herein, and no public announcement or filing
under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period or (i)&nbsp;by operation of
law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement; <I>provided</I> that if any filing under Section&nbsp;16(a) of the Exchange Act shall be legally required during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer. For purposes of this agreement, &#147;immediate family&#148; shall mean
spouse, lineal descendant, father, mother, brother or sister of the transferor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned agrees that, without the prior written consent of the
Representatives, it will not, during the period commencing on the date hereof and ending 60 days after the date of the Prospectus, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any
security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the
undersigned&#146;s shares of Common Stock except in compliance with the foregoing restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees
that none of the Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting,
financial, regulatory, tax and other advisors with respect to this agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may
provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with the Offering, the Underwriters are not making a recommendation to you to participate in the Offering or sell any shares at the
price determined in the Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such a recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal
ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall automatically terminate, and the undersigned shall be automatically released from its obligations hereunder, upon the
earliest to occur, if any, of (1)&nbsp;the execution of the Underwriting Agreement in connection with the Offering shall not have occurred on or before June&nbsp;23, 2023, (2) the closing of the Offering shall not have occurred on or before
June&nbsp;30, 2023, (3) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder or (4)&nbsp;the
Representatives, on behalf of the Underwriters, advise the Company, or the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this agreement. This
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Securityholder (Print exact name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory (Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory (Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stockholders </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invus, L.P. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invus Public Equities, L.P. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invus Advisors, L.L.C. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invus Public Equities Advisors, L.L.C. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Artal International S.C.A </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ulys, L.L.C. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invus US Partners LLC </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d512290dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g512290g0527034337184.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;2, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Technology Forest Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Woodlands, TX 77381 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), with respect to certain
legal matters in connection with the proposed issuance and sale by the Company of 27,513,410 shares (the &#147;<U>Shares</U>&#148;) of common stock, par value $0.001 (the &#147;<U>Common Stock</U>&#148;). The Shares are being offered, issued and
sold pursuant to an Underwriting Agreement dated May&nbsp;31, 2023 by and among the Company and Citigroup Global Markets Inc., Jefferies LLC and Piper Sandler&nbsp;&amp; Co., as representatives for the several underwriters named in Schedule II
thereto (the &#147;<U>Underwriting Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have participated in the preparation of a Prospectus Supplement dated
May&nbsp;31, 2023 (the &#147;<U>Prospectus Supplement</U>&#148;), forming part of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) on
August&nbsp;6, 2021, and declared effective by the SEC on September&nbsp;14, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-258564)</FONT> (the &#147;<U>Registration Statement</U>&#148;), which also contains a base prospectus (the
&#147;<U>Base Prospectus</U>&#148; and, together with the Prospectus Supplement, the &#147;<U>Prospectus</U>&#148;). The Prospectus Supplement has been filed pursuant to Rule 424(b) promulgated under the Securities Act of 1933, as amended (the
&#147;<U>Securities Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have examined and relied upon (i)&nbsp;the Registration
Statement and the Prospectus; (ii)&nbsp;the Fifth Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof; (iii)&nbsp;the Second Amended and Restated Bylaws of the Company, as amended to the date hereof;
(iv)&nbsp;the Underwriting Agreement; (v)&nbsp;resolutions of the Board of Directors of the Company dated May&nbsp;25, 2023 and resolutions of the Pricing Committee of the Board of Directors of the Company dated May&nbsp;31, 2023; and (vi)&nbsp;such
other certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the Prospectus and the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth herein, we are of the opinion
that the Shares, when issued and delivered against payment therefor in accordance with the Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vinson&nbsp;&amp; Elkins LLP Attorneys at Law</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">845 Texas Avenue, Suite 4700</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Austin Dallas Dubai Houston London Los Angeles New York</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston, TX 77002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richmond Riyadh San Francisco Tokyo Washington</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Tel</B> +1.713.758.2222 <B>Fax</B> +1.713.758.2346 velaw.com</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g512290g0527034337387.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">June&nbsp;2, 2023 Page 2</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions expressed herein are qualified in the following respects: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. We have assumed that (i)&nbsp;each document submitted to us for review is accurate and complete, each such document that is an original is
authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii)&nbsp;each certificate from governmental officials reviewed by us is accurate, complete and authentic, and
all official public records are accurate and complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. This opinion is limited in all respects to the federal laws of the United
States, the Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of the laws of any other
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Company&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> dated on or about the date hereof, to the incorporation by reference of this opinion into the Registration Statement and to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus
forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>/s/ Vinson &amp; Elkins L.L.P.</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vinson&nbsp;&amp; Elkins L.L.P.</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d512290dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PURCHASE AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;31,
2023 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Artal International S.C.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">44 rue de la Vall&eacute;e
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">L-2661</FONT> Luxembourg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luxembourg </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Anne Goffard </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2445 Technology Forest Blvd., 11<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: President and Chief Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (a)&nbsp;that certain Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;) being entered
into by Lexicon Pharmaceuticals, Inc. (the &#147;<U>Company</U>&#148;) with the representatives of the underwriters named in Schedule II thereto (the &#147;<U>Underwriters</U>&#148;) concurrently with this Purchase Agreement (the
&#147;<U>Agreement</U>&#148;) providing for the issuance by the Company to the Underwriters (the &#147;<U>Public Offering</U>&#148;) of 23,924,705 shares (the &#147;<U>Firm Shares</U>&#148;) of the Company&#146;s common stock, par value $0.001 per
share (the &#147;<U>Common Stock</U>&#148;), plus up to 3,588,705 additional shares of Common Stock (the &#147;<U>Option Shares</U>&#148;), that may be issued pursuant to the Underwriters&#146; option to purchase additional shares of Common Stock as
provided for in Section&nbsp;2(b) of the Underwriting Agreement (the &#147;<U>Option</U>&#148;), in each case, for sale in a public offering at a price to the public of $2.60 per share (the &#147;<U>Purchase Price</U>&#148;), (b) the Fifth Amended
and Restated Certificate of Incorporation of the Company, dated May&nbsp;20, 2022 (the &#147;<U>Certificate of Incorporation</U>&#148;) and (c)&nbsp;that certain Registration Rights Agreement, dated as of June&nbsp;17, 2007 (as amended, supplemented
or otherwise modified, the &#147;<U>Registration Rights Agreement</U>&#148;), by and between Invus, L.P. (&#147;<U>Invus</U>&#148;) and the Company. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in
the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants and agreements herein contained, and intending to be legally bound
hereby, pursuant to Section&nbsp;12.01(c) of the Certificate of Incorporation and Section&nbsp;2.02(a)(ii) of the Registration Rights Agreement, as applicable, (i)&nbsp;each of Artal International S.C.A. (the &#147;<U>Investor</U>&#148;), Artal
Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, Mr.&nbsp;Amaury Wittouck, Stichting Administratiekantoor Westend, and Westend S.A. (collectively with the Investor, the
&#147;<U>Invus</U><U> Entities</U>&#148;), as applicable, hereby waives (a)its rights under Section&nbsp;12.01 of the Certificate of Incorporation to purchase its Pro Rata Share (as defined in the Certificate of Incorporation) of the Firm Shares and
Option Shares in connection with the Public Offering and (b)&nbsp;its rights to include in the Public Offering its Registrable Securities (as defined in the Registration Rights Agreement) pursuant to Section&nbsp;2.02 of the Registration Rights
Agreement, as applicable, and (ii)&nbsp;the Investor shall purchase, subject to the terms and conditions herein (the &#147;<U>Concurrent Private Placement</U>&#148; and, together with the Public Offering, the &#147;<U>Offering</U>&#148;), (a)
24,152,218 shares of Common Stock (the &#147;<U>Firm Investor Shares</U>&#148;) and (b)&nbsp;to the extent that the Underwriters exercise the Option, up to 3,622,832 shares of Common Stock (the &#147;<U>Option Investor Shares</U>,&#148; and together
with the Firm Investor Shares, the &#147;<U>Investor Shares</U>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">I. <U>The Firm Investor Shares</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of the conditions described in Section V, the Investor hereby agrees to purchase the Firm Investor
Shares from the Company at the Purchase Price. The total purchase price for the Firm Investor Shares shall be equal to $62,795,766.80. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the sale of the Firm Investor Shares shall take place concurrently with the closing of the sale of the Firm Shares under the
Underwriting Agreement (the &#147;<U>Firm Closing Date</U>&#148;), (i) with payment for the Firm Investor Shares to be made to the Company by wire transfer of immediately available funds on the Firm Closing Date and (ii)&nbsp;with delivery of the
Firm Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II. <U>The Option Investor Shares</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event that the Underwriters exercise the Option, the Investor shall have the option to purchase, at a price per share equal to the Purchase Price, a number of Option Investor Shares from the Company, determined by multiplying 3,622,832 by a
fraction, the numerator of which shall be the number of Option Shares as to which the Underwriters exercise the Option and the denominator of which shall be the maximum number of Option Shares subject to the Option, rounded down to the nearest whole
number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent the Investor is granted the right to purchase any Option Investor Shares, the closing of the sale of the Option
Investor Shares purchased pursuant to this Section II shall take place concurrently with the closing of the sale of the Option Shares (the &#147;<U>Option Closing Date</U>&#148;), (i) with payment for the Option Investor Shares to be made to the
Company by wire transfer of immediately available funds on the Option Closing Date and (ii)&nbsp;with delivery of the Option Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and clear of all
liens, with any transfer or stamp taxes duly paid by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">III. <U>Representations, Warranties and Covenants</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants to and agrees with the Investor to all the same representations and warranties contained in
Section&nbsp;1 of the Underwriting Agreement and the covenants contained in Section&nbsp;5 of the Underwriting Agreement <I>mutatis mutandis</I> to the same extent as if such representations and warranties and covenants were set forth herein for the
benefit of the Investor instead of the Underwriters (except that references to the (i)&nbsp;Underwriting Agreement therein shall be references to this Agreement, (ii)&nbsp;Underwritten Securities and Option Securities thereunder shall be references
to the Firm Investor Shares and Option Investor Shares, respectively and (iii)&nbsp;Securities shall be references to the Investor Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor hereby represents and warrants to the Company that it (i)&nbsp;is acquiring the securities to be purchased pursuant to this
Agreement (the &#147;<U>Purchased Securities</U>&#148;) for its own account solely for the purpose of investment and not with a view to conduct, or for resale in connection with, any subsequent distribution of such Purchased Securities or any
interest therein, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii) is an &#147;accredited investor&#148; (as defined in Rule 501(a) of Regulation D) and (iii)&nbsp;has been provided an opportunity to ask questions of and receive answers from representatives
of the Company concerning the terms and conditions of this Agreement and the purchase of the Purchased Securities contemplated hereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IV. <U>Additional
Covenants of the Company</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company
agrees to pay or cause to be paid, within 15 days of the submission of any invoice with respect thereto, the reasonable fees and expenses of Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel to the Invus Entities, relating to the Offering and any
other transactions contemplated by this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">V. <U>Conditions to the Investor&#146;s Obligations to Purchase the Purchased Securities</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Investor hereunder to purchase the Firm Investor Shares and the Option Investor Shares, as the case may be, from the
Company, and of the Company to sell the Firm Investor Shares and the Option Investor Shares, as the case may be, to the Investor, will be subject to the satisfaction or waiver of the following conditions on or prior to the Firm Closing Date and the
Option Closing Date, as the case may be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The satisfaction by the Company of the conditions set forth in Section&nbsp;6 of the
Underwriting Agreement (other than clause (l)&nbsp;thereunder); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The substantially concurrent closing of the sale of the Firm Shares
and the Option Shares, as the case may be, on the terms set forth in the Underwriting Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The delivery to the Investor of
opinions of counsel to the Company by the same counsel as set forth in Sections 6(b), (c) and (d)&nbsp;of the Underwriting Agreement in the form and substance acceptable to the Investor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The delivery to the Investor of the officer&#146;s certificate contemplated by Section&nbsp;6(f) of the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than with respect to paragraph (b)&nbsp;of this <U>Section V</U>, these conditions are for the Investor&#146;s sole benefit and may be
waived by the Investor in its sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VI. <U>Termination</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement, and the transactions contemplated herein, shall automatically terminate, and the parties hereto shall be automatically released
from their respective obligations hereunder, upon any termination of the Underwriting Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VII. <U>Miscellaneous</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company hereby agrees to indemnify and hold harmless each of the Invus Entities and each of their respective affiliates, directors,
officers, agents and employees and each person, if any, who controls the Invus Entities within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the &#147;<U>Indemnitees</U>&#148;) from
and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any
of the transactions contemplated by this Agreement. For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be obligated to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease
in the trading price of the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The provisions of Sections 13, 14, 17, 18 and 19 of the Underwriting Agreement are
incorporated herein by reference and shall apply to this Agreement <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement may not be amended or
modified except by an instrument in writing signed by, or on behalf of, the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement (i)&nbsp;shall be deemed
to satisfy (a)&nbsp;any requirements of any Invus Entity, as applicable, to provide written notice to the Company in accordance with Section&nbsp;12.03 of the Certificate of Incorporation in order to be considered a &#147;Covered Stockholder&#148;,
(b) the Company&#146;s obligations under the Certificate of Incorporation with respect to the delivery of a &#147;Notice of Issuance&#148; with respect to the Firm Shares or any Option Shares and (c)&nbsp;the Company&#146;s obligations under the
Registration Rights Agreement to provide written notice of the Public Offering to any Invus Entity, and (ii)&nbsp;shall, to the extent the Company issues and delivers the Firm Shares and any Option Shares as contemplated by this Agreement,
constitute (a)&nbsp;the Company&#146;s satisfaction with respect to any rights granted to the Invus Entities with respect to the Offering pursuant to Section&nbsp;12.01 of the Certificate of Incorporation and (b)&nbsp;the waiver of each Invus
Entities&#146; rights under Section&nbsp;2.02 of the Registration Rights Agreement, as applicable, with respect to the Firm Shares and the Option Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) This Agreement may be executed and delivered in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All notices and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon
receipt) by delivery in person, by fax, by electronic transmission, by a recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at
such other address for a party as shall be specified in a notice given in accordance with this clause (f)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to any of the Invus
Entities: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Artal International S.C.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">44 rue de la Vall&eacute;e </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">L-2661</FONT> Luxembourg </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Luxembourg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Anne Goffard </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Invus Group, L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">750
Lexington Avenue (30th Floor) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: David van Zandt </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with
a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Simpson Thacher&nbsp;&amp; Bartlett LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">425 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
New York 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Kenneth Wallach, Esq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lexicon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2445 Technology Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;President and Chief Executive Officer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vinson&nbsp;&amp; Elkins L.L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">845 Texas Avenue, Suite 4700 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Houston, Texas 77002-6760 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: David Palmer Oelman, Esq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INVUS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Invus Advisors, L.L.C., its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CFO of the General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARTAL INTERNATIONAL S.C.A.,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Artal International Management S.A., its managing partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARTAL GROUP S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">D&eacute;l&eacute;gu&eacute;e &agrave; la gestion journali&egrave;re</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARTAL INTERNATIONAL MANAGEMENT S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INVUS ADVISORS, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Purchase Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">INVUS PUBLIC EQUITIES, L.P.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Invus Public Equities Advisors, LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMAURY WITTOUCK</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amaury Wittouck</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">STICHTING ADMINISTRATIEKANTOOR WESTEND</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amaury Wittouck</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amaury Wittouck</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sole Member of the Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WESTEND S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Purchase Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and agreed to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LEXICON PHARMACEUTICALS, INC., a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Purchase Agreement] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d512290dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g512290g0527035020767.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>NEWS RELEASE </I></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCURRENT PRIVATE PLACEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Woodlands, Texas, </B><B></B><B>June&nbsp;1, 2023 </B>&#150; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (&#147;<B><I>Lexicon</I></B>&#148;) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares
of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $2.60 per share. All of the shares are being offered by Lexicon. The gross proceeds from
the public offering are expected to be approximately $62.2 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Lexicon has granted the underwriters a
<FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 3,588,705 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about
June&nbsp;5, 2023, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the shares being sold in the underwritten public offering,
Lexicon has agreed to sell 24,152,218 shares of its common stock to raise gross proceeds of approximately $62.8&nbsp;million in a concurrent private placement (together with the underwritten public offering described above, the
&#147;<B><I>offering</I></B>&#148;) at $2.60 per share to an affiliate (the &#147;<B><I>Private Placement Purchaser</I></B>&#148;) of Invus, L.P., Lexicon&#146;s largest stockholder, pursuant to its preemptive right under Lexicon&#146;s Fifth
Amended and Restated Certificate of Incorporation. The Private Placement Purchaser will have the option to purchase, on a pro rata basis, up to an additional 3,622,832 shares of common stock at the public offering price to the extent the
underwriters exercise their option to purchase additional shares of common stock. The shares of common stock being offered pursuant to the concurrent private placement will not be registered under the Securities Act of 1933, as amended (the
&#147;<B><I>Securities Act</I></B>&#148;). The concurrent private placement is also scheduled to close on or about June&nbsp;5, 2023, subject to the closing of the public offering and the satisfaction of certain other customary closing conditions.
The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon currently intends to use a
portion of the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents and short-term investments, to (i)&nbsp;fund the commercial launch of
INPEFA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (sotagliflozin) and (ii)&nbsp;fund the continued research and development of its drug candidates and for working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup, Jefferies and Piper Sandler are acting as joint book-running managers for the public offering. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> relating to the public
offering was filed with the U.S. Securities and Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) on August&nbsp;6, 2021 and declared effective by the SEC on September&nbsp;14, 2021 (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-258564).</FONT> The shares of common stock proposed to be issued in the concurrent private placement have not been registered under the Securities Act, or the securities laws of any state or other
jurisdiction in&nbsp;the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in&nbsp;the United States&nbsp;except pursuant to registration under the Securities Act or an applicable
exemption from the registration requirements of the Securities Act and, in each case, in compliance with other applicable securities laws. A preliminary prospectus supplement and accompanying prospectus relating to the public offering have been
filed with the SEC and are available on the SEC&#146;s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC and will also be available on the SEC&#146;s website at www.sec.gov. When available,
copies of the final prospectus supplement and accompanying prospectus may also be obtained from Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831- 9146); Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by e-mail at prospectus_department@jefferies.com or by telephone at (877) 821-7388; or Piper Sandler &amp; Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell,
or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lexicon Pharmaceuticals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon is a
biopharmaceutical company with a mission of pioneering medicines that safely and effectively treat disease. Lexicon advanced two of these medicines to market and has additional drug candidates in discovery and clinical and preclinical development in
heart failure, neuropathic pain, diabetes and metabolism and other indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without limitation, statements about the completion and timing of the public offering and concurrent private placement and the use of proceeds from the offering
are based on management&#146;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#146;s ability to meet its capital requirements, successfully commercialize INPEFA in
heart failure on the timeline and/or at the prices currently contemplated or at all, conduct preclinical and clinical development and obtain necessary regulatory approvals of INPEFA (in other indications), LX9211 and its other drug candidates on its
anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#146;s actual results to be materially different from any future results expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under &#147;Risk Factors&#148; in Lexicon&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, quarterly report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2023 and other subsequent disclosure documents filed with the SEC. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a
result of new information, future events or otherwise. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Investor Inquiries</B>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carrie Siragusa </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>csiragusa@lexpharma.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Media Inquiries</B>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alina Cocuzza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>acocuzza@lexpharma.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Statement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon has filed a registration statement (including a prospectus) with the SEC for the equity offering to which this communication relates. Before
you invest, you should read the preliminary prospectus supplement and the accompanying prospectus in that registration statement and other documents Lexicon has filed with the SEC for more complete information about Lexicon and the equity offering.
You may get these documents for free by visiting EDGAR on the SEC&#146;s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from Citigroup, c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by e-mail at prospectus_department@jefferies.com or by telephone at (877) 821-7388;
or Piper Sandler &amp; Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lxrx-20230531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/2/2023 9:29:38 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:lxrx="http://www.lexpharma.com/20230531"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.lexpharma.com/20230531"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230531_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230531_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>lxrx-20230531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/2/2023 9:29:38 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>lxrx-20230531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/2/2023 9:29:38 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lxrx-20230531.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g512290g0527034337184.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g512290g0527034337184.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 *H# 2(  A$! Q$!_\0
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MX?$>E-C;"EI/:N,K*@ "G/8@ <X/2K$,\FL0)XLF""6T0QVEL1E(F8@,Y/\
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+M;J%)*=^;6Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g512290g0527034337387.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g512290g0527034337387.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 #0# 2(  A$! Q$!_\0
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LT452UT(EIJBO<:=<>)IVU"_NHO-X15C@P%4#IRQ[D_G1111S-:(%!/5G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g512290g0527035020767.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g512290g0527035020767.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +D# 2(  A$! Q$!_\0
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M^J]@\TFGVTEPFR=HE,B 8VMCD58H **** "D(# @C(/4&EHH :B)&@1%"JO
M ' ID]M%<JBRKN".LB\]&4Y!J6B@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140583593758080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d512290d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20230531.xsd" xlink:type="simple"/>
    <context id="duration_2023-05-31_to_2023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-05-31_to_2023-05-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-05-31_to_2023-05-31"
      id="Hidden_dei_EntityCentralIndexKey">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-05-31_to_2023-05-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-05-31_to_2023-05-31">2023-05-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-05-31_to_2023-05-31">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-05-31_to_2023-05-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-05-31_to_2023-05-31">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-05-31_to_2023-05-31">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-05-31_to_2023-05-31">2445 Technology Forest Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-05-31_to_2023-05-31">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-05-31_to_2023-05-31">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-05-31_to_2023-05-31">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-05-31_to_2023-05-31">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-05-31_to_2023-05-31">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-05-31_to_2023-05-31">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="duration_2023-05-31_to_2023-05-31">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-05-31_to_2023-05-31">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-05-31_to_2023-05-31">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="duration_2023-05-31_to_2023-05-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-05-31_to_2023-05-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-05-31_to_2023-05-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-05-31_to_2023-05-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-05-31_to_2023-05-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " #B@\)6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( .*#PE8<.&7J/P$
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M?P%02P$"% ,4    " #B@\)6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .*#PE8S^@,0[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( .*#PE:97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ XH/"5FS.8/QJ!   /!$  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( .*#PE:?H!OPL0(  .(,   -              "  :P,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ XH/"5I>*NQS     $P(   L
M ( !B \  %]R96QS+RYR96QS4$L! A0#%     @ XH/"5APX9>H_ 0  / (
M  \              ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M .*#PE8D'INBK0   /@!   :              "  =T1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .*#PE9ED'F2&0$  ,\#   3
M              "  <(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(   P4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d512290d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d512290d8k.htm">d512290d8k.htm</File>
    <File>d512290dex101.htm</File>
    <File>d512290dex11.htm</File>
    <File>d512290dex51.htm</File>
    <File>d512290dex991.htm</File>
    <File>lxrx-20230531.xsd</File>
    <File>lxrx-20230531_lab.xml</File>
    <File>lxrx-20230531_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d512290d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d512290d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20230531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20230531_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20230531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20230531",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d512290d8k.htm",
      "contextRef": "duration_2023-05-31_to_2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d512290d8k.htm",
      "contextRef": "duration_2023-05-31_to_2023-05-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com//20230531/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-23-159886-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-159886-xbrl.zip
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M*_)-_E8^624&G'L@_!X/0;J0RT<'G<[Q^N9!T9Y:7I)=4?+DF#Y7^%LY-?P
M!J09DHE#;B,0DHZU9R0T5VJ$%48[K0/2^W!+K':S#@UWLXYQ81;\36Q7,^0
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M5#0WAYD(?JJ .)U:M[.MC'G=GE>0$>'[%&T(D;0NZ6,&##=_F>,$3+=\Z'0
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M_T;;6[ 6< /\16=5HE=[@2]]ZK1Q[VDQPFN,QM[DF*"3-=,%'IZ)1.:I=_I
MW_N$#?R1?P29;<7LG.0S>!T<!MN><*B =D1Q[K7'7M%O\=FXS8W\1A-R"H=0
M,8?#J[XR\Y*\<Z=49XIH*<VO^L\VV0;1?&\VEY?G&$8MQ'*PVVI["_8[;BNQ
M^U\7:+CUCKO'O(Q'\\R=9&XZ5MRP5U9N<+#73=O57OVG\O96K+TBW477!X<H
MF<CX[% 0-IB53[();^1?'Y'F!\'(RW&NMK(N^)!&Z1DYJYFU$HUZ8HWPB"H&
MQT\L$1@-C1#_@4+#1F'.>[D:+UEUP:<2">!MZE^JE;>R2WT"KY(<'*(LOZ[
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M/]M+,-7!J=C^*P;?6^910CU7(A)A/K9H@E)#BUHGJ]H#Y]8-E+!$\I*Q;J6
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MCJPQ7I5<:YJ&D1^WH]@M+!63A8@#Y)5=-@5&!IAQ.:_9D,)_96*4R+]A<_'
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M>K7M!BIR-3_N#?$M@D9E_!:;]M<'IGY^+8!41@QRF69%O0HN*WZA!QWX:5Z
MY6SC2+%M.8A5,)EW=K_1?!UGFE3C.2 _42X#Z]VZD\IX5$C?&\D@L'VCP1.\
MTSAKSM&POVPTUJ\%$@9XL ?KA=44?>+C0QR.3Z\'&P<^"O83PG4>H^&63ZP:
M%3@%01D6#%9&HTNA9K@(BA6JJ^49%]:<>X1$45Y4LPM./6J,B\DG#).DU-J+
MW1W8"])!HJTX!TWN4>:"'QGA_/\'AM%0(<T+]9+>N@3S&YCM97864C@-T\NL
MCK5]CDTE,NM* MH8%TEM;;:W&&$X(-B>,2U:W9BH8A"4<K8L,'-6ZL(*,%R*
M/8<>O)?\7BE3:9_(27&VS+WID&+PX9YMQ ;U/EF1K2\BO_M WB)$D^'\*TT>
MZ!JL1C?Z1<HW&#'O87^CJOJ@_-RXQDT 0D-*S*L&:9#PGHI>,!O90=*:Y91!
M,BUG&PGS;4&(X.)P!("<=1OZLXXR 8843= C>![+Y."'K&A(1@1*"S:59'=I
MU8/\>OPP?FMV[@,JC@6!;F47.#.V5SQOI/Z\!A0E\6=) "425?$_*K,@8D=+
MS(ARLA0V?+:]9<W8,;X*%Y;@M^BB+!R,F%# GSJ[26=R;>;:S^?00'$H: *0
M;J''YA\1BTM-WNB"K W1JR!V%YG 'F&RZ@KFC\H=QA*0!G6.1>H=AY/BQ,54
MM+#&5^QPOU'-'U!5;:;ZD[6:OVAN0>=_!5&,?W5!MSY#$ZR<S()B1(Q<1MT8
M87H0]IPX9$:W*2,=/G^!C=F ':?JHPA(Z)2S\MRU49.1@!EY*>!3V6PMZ:3J
MLL0R* Q14#41V7^Y %0US: J S,7RW%+W[HX+[FN85[W5F53QD*.D\9&)X,A
M?9W%(.HSP'8J\'<0_AFAB.7TC]8%9)[L57*E>591$;E)Y0I#=KM]>F@@+] !
M+)($2:B#7'F4$W0_P0\,Y(4XS/GD,6O!TM89LX)^6V%U>I]_S!ISNI.=%$@6
MEIPH2M:MNXB;>YQ$;CVF!&.^($M2(BL"=.6:^/&<!8&<?NI9J?GLKD93^<EA
MEL/NRUYS ;[5>,?C[_&.6]7Q]2X7@/9']Y5+TIO#6C,1\43$(>=K-TC8776\
M8&)"V_CV$R=N>@"E%*RQ&QE3?_ (GTT<:[%$9H_E=.#HX@R*.;N2]4>7?YWN
M4=9W@.WX\TU3-+MW>JIM;WVBL_TU'4DKQ#[P_^2XVM[R*GGHN+J!=%WWH*,3
M[0N=9>[55QUF0\MX"V<9%B)J2:4''EN\;R>=RV>_AT+U 43AEKF7"<?PTRL4
M,4 Z!&"K&N+1I6M1V SOS3=!G:VFE$5,ZZ5)K[C"+TM'(J'!*,M+G6XHFCL&
M@:@UQ2IPL2LW3REVJ6C/B.9L063BB+O)42K*\7(^XE %;DP%",VR8I[LQ- O
M_$W##;1S3_*,<"000'389U7&JM$-(?.G"\>!.?3[6U:/SZ5AR^,T.=P_/*2:
M/FW&27$9(NWW3%S$=>0:?6;S"I5:,&,#3>:3'3P]_PO?[&I7.\[_\7&*E JO
M*<:1)V_>'+.ZG.545&R:5SLNMX.] Q?=PP%&MS@&7[)HD]<P+]BK"(9S&C5Y
M>Z/3\TZGIZ]'<VAY.PX'K.D35$Q=(>9CB*Z&*R>,@@.AK<9%A#X48-, @TE0
M$N:$[LI:")W$YJH:RGO[AS=/:]+ R0#G?17L;EDO$,)7 KH]/!BH@;0U44=E
M"9I.0AY1<YI5+[1_[^][.JX[=_H;Y_3[TI.=L.<V%XGL:NSNLU34W&;B;),3
M8V6IS<VUN[FE# !A&C%0 &=QFD\H<$B:CSQ9@]A%.Q-C_J4C6!I\!R1F<X]*
M+HIJYB$%W#%6RUH8A)LJ&)>"M35)]739&-!F#\@X+']AEX"1/6;0H8VUM[WU
MWH*;S>3B+<SK=,I0TD\:=5_)2E6O@$5+74HA,=2@%H76D_[.ZW'!RTOU**0H
M5]4680.003A3:PBQ$ IQVZ&F3C;F3E5.VZ-R.,5@ "4#W4<.J!$UK C\X\P1
M)7:XT_%V_A3&2W[/FDGVK^VM7V;5".;F73[#V/=O1&%A4#Y\60#ST4FU<5$.
MHZ,XCY7>0\OUN>RIK_:5= )9T$R=5TW3Q+$=BJX-X?Y.I/Q$#;7'J*D2KW$W
M"GZ$.-+M+7XW+/FJG?_I2=*DIPG^@6U6'";)V?F(?X!?\ETX.:&09'JH>9,N
M((><HT:JF7M/5M>L)A5&QQ!9M1KZ0.V;?$Q='H5@_1 .P8/_=L-C3[Z'QVY5
M-2UWX<]"U+/?'>4*;"I+:G#@4E(9-B>5RG,E+)[D8;@@L]A]7^00?*PGL T?
M(9Q9&_5TP@I<>5^@0IIFZ%GOX&'ETE)"W0E#U$Y*L"VSA32FXI9;6AWB;[)K
M].-+_LBVF6:-1(T*>=Z7B(Y'=RY-QNS7&$\.8242Q4)'$@0;PUG^>_)1,D1N
M3M&U/"\:4XB+_:5J[@CC;=2T!]?/!S3[J_;N?;ZE^K>]C\&%]QD6@E./Z9EG
MRXQ\6:R@ (>*;\Q1*XOQM!!Q"N+YF,T&N.="X697(D929=2:'\&MYHKI&57+
M<J+UA'RMOZJH$U.[9"*&/N.,QR8,X"^JIH@]>%EZBB*.-8*SO<50(F%^V*B6
M8/,$QAT:*1>A)N!>09EO]<GA Q/4+@4)XXIXC/6M?-%TP37*>E)W5\=(FVK%
M_97-$'(0)N:J[82%]&[@ODR+V<Q2W7#C*?'6A S3$#^F?M7 KDWPS,#061TH
M/M8_<XOMH_H:"A>A/N1-9@-'0AMWY4.17AJ[%15#^\28BVG8'#O0PC9LO_ZN
MG4;:/$7R4D;5>94E:LU'S"9(*H=/K)>-*#^K>CCF%1P$)"GF$EOI9&KLL&2H
MS+0^TZFK&RH85!^!]J#@,2<]BMJO4=%X-8'E;6$_<'1CEZ3EL\N4\ \H/1JV
M29._EI,S>;FP/BD).5(W? <M#L%**/>@"O;'J)I@2&L"9JD8HE@B>P;B!Q\'
M]5)R93TJ\#)V;25BY/,-8+ZC4@_S/1>1I;!JG,%7O!/]I%H""=&:3)X\%3KV
MQG+ *Q8_Y)K@79G:/1GL1U#<-O3N7!2KPC>L!]M AR?2J,(_TI+_\*6.!H@?
M$59&!LPA-RJ/_ J<WLN05D K])IET::F%R<>H41"R#-_@42!9T*&3V'\5GHZ
M2"=$TJ^P++-.#: $:<&K0MRRIM0VZ WJ.W"FVM.39)<Y2[Q[N59]L@IQY<:W
M827\;NJ?P]I([J]$1R>(1765=R)3G#5N;"*F$X=9F7[9:#;1')^#!B(:H#B4
MT,?EI;ELNQ"\C_DN_CWA]!G1(2K'O'W1(/CD2?FH=5-!E.4@EDLD/X8CK&Y<
M=@ ^J&IAI>25^R:LM8^TNWR7CKX25<Z?:U;9APFE\0KMME)"D(N,<IQR'@4?
MPC]@FB8YLI_JOY,RFZ/$-WE]@6Z5_#FN%E<:M^3K&CSG!$:HOD:;SS 6A:D$
M=\!>)R"(32EOQJ/:2"'XMQH5>?H]*O)Y":4YJ4PQ.W+0-<$\3[@(CQS+.M<"
M5,Z!.%"X4F,94$+'_52$ B.[J=Z_Q'RD_(:?'GR#>X,RXXPS\!?NC"O:0$2G
M!?:+BU6<V*UU*EO+1BXRTRM[.!IYC5?QG:ALN\RBG&)H@'R?>=%89'81%:HK
M)CNF#T.:*U07#2=X>]],ERTJJPZKXB=H?/-%F9('3"G.FI/&"ZQ;!>90!@Q'
MOX0#"%9WG#N(%/<WXS,<_8ANN+Q N&IPPN&ITVCC9SIC**V863 [5S4%UBV-
M7;2Q!I$[J VW;J9PXJ9 "UG-$#+_YG^>'AX<8+?/'H^+NMR/I=Z&N)R(JOPB
MUPVU&U'^@+E:3[B/5-Y(E>M%[F$KX-=45]D,V130'>O<SQQG^/Q>^1B BI@P
MSQB<5% !-:8#J ZZ(@(&+X,TS'OL+_*3J[KI3$W_T[GA2K,QL=)G :!EC5=A
M78^2\JHUNNMYGP7K:"8"EHF(%DPWMX^WV)44B=]\/?:LE]!KN*]25,Y>''(O
MR,XC@(XC7?[)\_B,L5%W7IY%1KZK9& YX'X!*R5M8,Z?>2*<^%&D8I M!(1;
M58QC>VG D,JO/Y?4'V?GV/5-:W)#>KMI@$26UW,=DOI@#YNHBFK682F'LOBP
MF,\Q7>SY4%T2ON)3I':6HC7TV%VYQ=K'3"L'#"=4&AQ/\EX2/B=[UYB[UMH-
MC5UCZX:FK@VJFW5S*@4.+7.NK33?22.:$()KW^/2&RY 1\%)'U>SV616UOU"
MY"#)*W0&'T<*:I)NG-@I86D?2:'T@2V[O653G25A21(2>:Y=(#][@RQI<( 8
MJILII47%LA!W5%P7@FQT79NX&+1_>C9=(LZ-F[.\:?,%4X#"!F@I:.C+]"BB
M/LTQG3*YUKD58I2"CFW6PBHQ9JJ[A4*H4Z)EPMUI\T""OE4?$&/08'_SMEE_
M36/)HIP?GJJ%V<NV;I82%E!_% <I"E6X3CC[X#W,330UQI(/?>&J398<5AO#
M@"K&FQ,DE[M1=)E5HN+*4Y$9^-E[50;)'T3?KX3A)&6@=8+&>6"?A3=2.62B
MX$\4Q%Z!,(BK(1WQ3):/<5<"Y^8F!(U&=QWFR0 '4K_! SS!RB=N;^$CM6<M
MZWV<_8)9"[X@XJ=7[0^0+QFXYA1?VG1><(<P'7%H0[!;8FPH65UB4NM;75VW
M5"!6;,/. GLA73VL;Q>Z<;#_/4IQJS' JX$J?R/3"V+ZDXH]]FJ)ZH.##-M;
MB$5GY!,I;UN_S6<G58:'VI) FZG#<<)5JEI,*HJR3I($&E43_)>IT?F$Z(CD
M5CZ3&F%RI75ZQ'!A\3P$,#GO9:_+,6T8W>]'WO%M([ :)[^]F]/EV4(6*279
M @>:ZP/&P1G*Q)A> B(!\.O/-B08P'#_H01&P7I2LJ3\"-#"T^RBJLDHFN3C
M@LDCZ^5,/+-I40J@Y7J1]SM-;/U[=R-3U>0;B!\L&RMSJZ]EXVVF7IAD*K2&
M*20!JD%FI0!N<A.DH.2J&\Y3-S91+59*-2O&!M:LN<F]=WO):^T>][)>GL'*
M^$0SB$M8OO'ZY5$4>11N!Q8&_'VONEBV2*KI,Z)H3$E;S<:FZ4U*/@J()L$X
MWOJ''$EF&YX35)#<=2XGRUB1&]/!69.RQ1NO B([AAE^!;##/*H$V#&M*GP#
M9@_>Z5.E-[2Z7/A7?&I;N?(^3?Y$N?X?'0J3#<(?OU *MZJ=O+WF<P7K)=#A
MSAW/3&V015YH\6>DR+IWO/N5'8UV,6,K'>E2]M,NL+5@H&E3V^66C$G!B1B@
M1R?=S;@..5^ON/^0'-)%?P/K8?R \O++D<8.E;7W7:.]E6R)^CL!Y[GQ& X,
M 6P'Y)0"TPXZ!@<7O';<.B=@#H#"N4IZMO455ZN94_OUR>]O.UH(;SB:80?=
M#U>NKAFG.2XV[9M"5_Y!VROBKHUFI:\=C.PTD(X2L38]BZ NV\TWY-V+_WC<
MVVH J_&N'Q*_2:N!#8(X9WJT<9-/AF1ADQP*_/KR*K#P9@I$; B<['+8/L>M
M>#[CML_!/]9^%NZD%EO-5R_'6 K;55X+6)/5]:N-A^,U7+G:!*6K^!>6!A%B
M):AAM5EZC:H9J$C5@31Y(!-V%?1=-H,9F53;6YP4%*;QP1R@VV7+1KJ#&E^E
MFQ#E_J'Q(WNR"[QF>D6* #'0PAKJP,E8N*Q7=U7/\YEJ,*8BV)C%&10:,E_[
MWWL'S&05^:[2])%?AB>=+;+&-6WR?0]H5N/5\//;G<>J7CEY&\X/^P/1]'1G
M@ROJ.Q&,.]1#DXG50\Y;VP27=3V';GLK]NC6*I^=H$FG-+9!0\JC"]@@2K65
M>SEQ#C?2;LSE(U<\T&8?87#@=K +3_?EY9I=&0YA8C5HN(&5H*##[!__D"H^
M83QPU]R8&"Q%]"W3IU,_-T5,D#LX$?SX(KOB[#F77<V4\40CCUQ(RKH:JZ59
MSDI,_L+>N" ^"D'EF0J 'H)/QO30F:KES3;F6_)03:C<^L\RK8KUF,"+XB4U
M&Z&-]! H?%$O[.Z(!VU3:K]O.*1W\#VD=ZN:*L\5-:LX";39IV@]T_[KE"I/
M<_Z4BPT:Y>S1X!S8MP*\#DQ=">')T84>/Y$_H&9"A=B80O:T=\\/F,<^*=5U
M/R/V).?*:6V7=@1S'>=]&Y?*EZ18^*<]<]#E'5U%[1XZ)KG86]8DO_O3:3K=
M[>EWFX:0*N2 DNH<[>(^SHM%2QEET+#,]R@3)4TN*[VV[0TN)"ZV0$O-K5=L
M6( GG[VI/QF9?RH_$9:L+V"]6^G3>FEN&*? -P:-.P)Q"<C!Z+S;>>(O\2T0
M*$AY\/3!/A<5"IE*&,7J_V$G>G2G\<BSLY5LOSW%F[@*OOF.M!-%?M8S8B +
M^@XW"V3>%FB*GL-,<"-=A(@BN&@^:+)8P@!S//B< ;NHEQ.UL3WJ2N3'1/\=
MR1-'^/(2_9C)!IGXC!V+OM84#B4AQ%H2W^31:B71<#M AV)W6IE:__%%XCAM
MWMG%%8^:T5Q%14V9B71RZ94R)(\-Q61>7N'&"MI$H=MF>4<S,6#<OA<<"E?8
M/ ,K<[CVE\9G<DGG68/%CP1UF!(0-AX;*'O<UPV7;>!MA, 8%-,SP<Q>ZWEB
M,J()SL<#W.TB%V1=:[5CHC54X"O"WBC(=95@4\\0A3:3>OMR&D2_ 1._$.7)
M02]P9>2L==>0JM1/W1[RAFA %\V=N99Y1$S7$ARU$5JQ3R"[O%.=<WY^LR:2
MGWHT6 I90I$8>>GB2(+0 ?$<83'.$!44K2H<I5243OS0VDPJ1#7)E?/L@UXI
MADP0#BQC>=8L4=0SBNZ%Y,I7)GGG-=T5E4QR36(VN:  #A/3A)O%I0&,"O+-
M_[#=G1OL=&AD/16I T6);=!$*Y[ZKT ^L5+PNKP&CN9D6$1H33H$*&R?9BVR
M;[AHP65<!4:Z +4N5\SK+F^8"-VG7.$%BH5);K"E5HPM4,H3G50N$,@VB^<7
MU\"@$IKV\)6"SQ0QC/TV1+>R$R?4X.KMK=^,);3;V]7+#M:W <3V+IP/U=I&
M+C*GB>%R\\B0=2KF[NWUO_[:C2B>G%;G)#P83.?%HG',"+DBR*-&G-BI9//R
MPG#S<2!N76?F6V7PUB9OTN>0Z<3<  S$[AN.=QQ^CW?<;N_Q#]?7TZ6I#1CE
MC>],-0S'H#)3AS>M*7?:Q@9##];YG&RZ22YIV-*<[QJ(4=];R@,(74F=@)D<
MPB$@/8M:%,\U^"F&9O;B7260HVA$T(N@1S#2$VN +Y=9^PJ.^5G0R_R+0DR1
M2-9'H!T]S.W4?1N.CU4>U(9L363%^%1[*(_(T3$.87V6W@)[R3@<^A2,A4S@
M"*9S#=?7X;$//]CM$F(D#'!@)EB+:^<L_*305MH1DP5EN!9UWBI/FPM0>N@;
M^-,SMT,%?2^O?;X$H4G.\VP&9LI.R.UL;P'+Q_( __XU^W=63RH\^71IFM3W
M>,QGU257MB5Y>5'45;D95=-\1/V0LJ+&BJ4:;*$\N<3[I\E9C9PD\L>,415\
M0<4FM_Q%LY(1,R"XP9-9,;53V?]<"@%3N,9@OKK 04YS4F"19I.I*8G0% GO
MZ"]*+,G<<'74QV*,G)QMWNA(6_%6M 6SPK4XDJ?"(-UW0VR+I8:WT"YGA;J%
M<5O&8KJD7JL-4'BYU(4U#4V0===23)5B'4^>4; /^:W:JF9&FZ(!><#]0>8;
M4]_BVY>3F7"+]0QF<."OO)S B[Z!%>FV6-T,L8#!*L'G=J"[F39$HO9([HS0
M%!T;^=VAX)97[AN#4%P%R<6V7!AL7!E[8_2?</F84-PFHT\U+6E9CM;/3@";
MQ5A_2_R5"IVEO(>K-<1W=J6$/J#F8W6=J=)"%WK)5=0BOH(ROU#*HS'/IG0\
M<^#7]9EFWI\:^/=1,WZOK^! GL]OD&E?>PS^%%)=14(0M;4C(7)^L;/^1K#&
M4VS?!KJUQS4V[J_^XFW>2@4,XLLPW^X9R36)\/B!32*8)LPQN!;[!E-V*SS,
M) ?#3Q]4'6]/WEDX&[BA.88/Y(X4.W )ZD[U6(\[R1N=[T\W3XZFB$1$K&W/
MW/!QUQ-I7PU ICL_BU[#/\F_4#+/LU*!,-TX@C'2"6S0Y=\A5%$^'WGH))ZF
M"ZK:,822D:4H=+M-\N#@P<X(=? 8_V=.I\A.)0(G._M$6QV^Q>V\Q($QD.;@
MZ9-'GU,&R*-Q<X9/"<ZW:3_M61P6)+HSGA+;[!"TD8:+\#PC,Y#4T^".H$6#
M:3%,SECF?Z%I1S^:M73P]_?O3;(KY8,7E<S]6ZECWV564 -7=+Y$53(?4&-U
MI%60=%5OC[_UF_]F.\BGF0N9([.%GME3RTUY/!BPLK[(: B30_+QS49C[G^/
MQGQ>VIOUV^,2[1=ENL9=R6<Z&Z!N@W&R%V5O6:)32(<%WTNMJ:+W2+'*A1N&
M]J4(>Z2]- =!O[R3_@"'R.F/CO)HF*\6=0>%6"*[;R>3K?N>8,"P?/ L?DKG
MA%(J<,\*BI=,ZNP2C@K,PZ0;JB,\<D;R7',P':;)@Z>/#^A_'Y+!^N#ID_T7
MWMZ<Y%$/4S+*[U3])4J @L<<R02'J'RW))[G@.[^P?[!3K9KWXL*?:J@F2(U
MH, ZW;/@D/#YA9%+TV 8P[=K(LY2R\,S;'1SJH: 4U7C79:@4=178'"7Y=>0
MB+5NSJBN/F#L FO[<D\L*J2K*A-$UCA3_X;<M&X.$_^?;R=LU7Q/#?!.<T-A
M+7]@X*EH&B'_S-2K4-: ;XI!LZJZP)Y-<2]Q?P!B8_>=>8U-ZH"TE[2(LEO
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MV"#VJM/B*XA-VJ#E@J*"*(/[;!>3FS1(9"RV^9#G"\X4H@V#L2NJ)HZ:'M$
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MV/?>G,##]Q7H[&H.OB\EVQ7/(+\[ZG88\S0T)Z='1QW'<\?.D3AQ13YF3IW
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M&JW+N"[F5.8QI9N8,C)D1#=K\XDCSLR(#YYL;X7#:I+#)X]HA@^?/.8!=1?
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M5J !WGE#JCT?Z.0EW!YH(U!68[EPA%IV&S9V'VK^#IL?YP1M0BB#V9C;6W2
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MVX;A#UJT E%79#S?<6?'CF_H;%KAGG)V<&\,N4I<A977$ZMF&].1XQP=/&P
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ME\K=%7,A/D.?6]VE0@V;8P=+,;IBOW*H>F0#!? Y&"@^V9:[4^5<1(V?AMO
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M'BSXE>,A6+?@:%H,O8"P*?6^1<JHLC.<>5-<.<LN#0\DQ>TT*E0K6K_W^Z\
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M3X<X23C0 T[->QP:-P5U(U]]A'7$4MG"@@)^3;:]S GK Z>T=@Q7,"OG^94
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M>=Q*.(2$$F JCP:(I<V?JQ;I8YL?PS+1E(A7SA9O<P @3:!B0WG8H*5!MM1
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M7>#C5[C 9,N_WSAM>9UM(BA9R;%:',BN+OY+?/BU\ZUU^O]02P,$%     @
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MD8;D._@RS,SSS6$,T26-R*=5/".BV<24\SH=#X,!;C[N#OY3+5S*M3ID\DA
M8_=KH->J:0Q0I_[F*E072_2>9C?'GT-MI4BG"!^RQBV"W>&N%<8E796"W5JX
MW+=JQ3 $S_"#,1)G8:@,R/R?:\K(L-DX& 4Z'84Z2_Q H/L(5(KBXI_KORXV
M0%>"&X9U'=.:#0/ZS_#2#OHC5_1'+P[]D2WZHS;0'WT_]*=KWAKZ2#:LT:_U
M@HC^1&W>B"E?LV>!7TY_"=@;[)B@?PQ#0_ZI9$O ZS+ !>A"N+!C&ZA#W<X%
M(N;I[\,WXE;P!\J"AK=UJC1> O!5QDS4/XE%0]^HVQ+_V8T-A4Y1#7<(6K%2
M-PD-_"".PRV7B1_]39?-[W&:%5["*)A-F09A)Q)M# RJ+0U!5@E4*<S[ENW9
MJ!L :R^.[P!J@X+X38#?S>GJ#4!3XWS_F-/[?WLZ2."F/^>U,@ZG^'WNO/MG
MV:P;B/JEW.AVP5G#^^7[>1T!66F FX^[@&G60H(S%8=4'>N^83O]EB%MTK0;
MJ'<D6 DU$L/1;$J3R'K5W,_K"-1* ]Q\W 54LQ82J(4X*'5(Y9U!;:??,JA-
MFG8#=2I\_=F5NVT\XY$MI4^2.D+4W#HW''2!TR"$1&:N#)FT,Y4M-%I&TK9;
MG'7S8A,LE%O2Y/4H<V['ZZ?1"*^.P5A']_6PU]*B L[K4>WU;5Q3+9MW _E/
M52HA;,+C>,7R!Y+2EN2*Y(Y0KK?":X)<8*X11*(YKP"[)9QI;K'Q,LY-NW=<
MEWE$ YJH'P ??=4%]:VO%4R97:W)U29X5833>ERAAK4:?Y.'0M]]*6ZIY9V%
MN$G?;MC>"J+G@R@LTH]"Z(_'BIO[>_L[!W4*'6%L88H?BG3!^I J$MZJ#)3K
M0%8(TDK.H+=MH@S\,YV@HG\EY8H(]P$PZ+R,,:@V:!Z&O7C$D:C0;FLPLG*M
MSD=+CFJGI)$MC.=[%S$1<_5CZ3?!U\E"];+T6<,/\E9(=/J$K]X6/QCJ_HRO
M1A9I)O('8T4AR"I!7@KI&5^+-@P/^6R]E'=<JRW]7Z[DNVCV'X^H/?\#4$L#
M!!0    ( .*#PE9H(R/KP 0  $ L   5    ;'AR>"TR,#(S,#4S,5]P<F4N
M>&ULU9I=C^(V%(;O5]K_X*8WK=00/G:F QIV19F9%>I\(&#;JC<KDQS JF-'
M=AC"O^]QP"V!, NSVRJ>BP$<O\?O.8]C89/K#UG,R3,HS:3H>HU:W2,@0ADQ
M,>]Z2^U3'3+F$9U2$5$N!72]-6COP_NW;ZZ_\WUR<S=X)#Y9I&FB.T&P6JUJ
MT8P)+?DRQ9"Z%LHX(+YO^_<GG\AOF^$Z9 0<J 824YV"(K\L&8\ZS7JSV6C4
MKVJ7NS(%U,0C$4VA0RZ#9H#]6J3=:;8[K2LR?""W>1!!)BR&7:5,UHK-%RGY
M(?R1Y*(;*01P#FMRQP05(:.<C*WAG\A A#72XYR,C$RC2PWJ&:+:-BIGXJ^.
M^3<UWLG;-P3_L(Q"YZU=SQ1C6XMLJGA-JCFZK;<"*_)V-=F!:-7*)8UVNQWD
M5XO]-2OKC0,T@C\>[L?A F+J(P)$%NX-A6ZB]!_UKKF+8'/1]M>LH_-(]S+,
M*W]"6N1H#_/)M]U\T^0WFGZK4<MTY+TW0VZJJB2'$<R(>?TT&A3&Y) E"ZIB
MFD^I''_]HM4(4II)(>-U8$3!C0R7,8C4OO9$="M2EJX'8B91;%+Q2%[5SD+!
MK.OQ3&6^C68,?3_"0)_/"92N$[PO-(L3#AX)=A)*%$X>D>:][[&A(( L!1%!
M9,.8!/ZKE-]ON&XGKPP+);!W;PY-0UB;R^<@ F9&;)HWIC[-O#;XX7-?XH+1
MF^I4T3 MUH";V2*5;>1T"KSKE8B";VFHAVE')O4[3N>G&MH3%0WM<NNIL!"2
MJM"&P[<'T(HS?]LC2*C">'ZXP"7.JF=*QJ7%V8XF2XU*%8'J>I@^WO$>2123
M"F%CBT>6&KW(Q+BFW%R#&2@%T?TF[:,N<XNX>FK(>WYC/)O9V,<,%.4#G/'9
MK[ ^%=,1<75Q'3%LL;6<P6;7DPF6\51:14UU(15]6C87SK$9 GK%Y3ZZP>]%
MYT+:$U>?UIYAB^W2&6R;M6$$<V82%>DCC4^F5JZM+K1ROY;9SXXQPTV!5(E4
M>6G'6&'HRR4N\>N^C,Y$^(5052?Z!?L6\)5C@.\8A\=E/ 5U'LU=7=71[7JU
MG-J.<9K0;!!A&=B,;3:FKX%V-$C5"1XUOL79JCN&LQ=%6&2]?<$M,C3.0UD:
MH.H82TU;A WG$3:_%F'3183-?Q&ZMC??9M''MT]J(E?B50!WY8[@V[5LX;FS
M0R^DDG\5>U)#)9^9.?A]#<&#&(Y@//!M6;YSD^50ZI3R/UER_NZB/((C'/=<
M6XKNG,N8]:2G@)[#K:BI+JFB3\O&G<,7\TL6'RZD.'.?=ZBK+J-#KY:3.P<N
M8PB7QF*C.9VPE)]\'QWJJLOIT*OEY,ZYR411\YC >!U/)3\5TIZHNH3VC%H\
M[AR7V"EVFX4+*N9PSEESN;:ZL,K];IF]<^=,Y'?TEX+HRSA>BNT)CSX5VA%Q
M=:D=,6RQN7,.,I:<A2S%Y>(!]R&*T9.7PS)E=8&5N;6TW#GR&"HP4PYPHYC_
M!&R>P5%/L]GIWPA?BE!=>B^YMA3=.?O8RV:@]1+4U[,LB>,,T1+OEJMKYR"W
M,:@YKC,?E5RE"TPRH>+,1X:.A*@NS1=M6Y#_PU'(=7!0FGML,(^^;JZ8?^9!
M3FSY&U!+ 0(4 Q0    ( .*#PE:O>7VY5A<  .N4   .              "
M 0    !D-3$R,CDP9#AK+FAT;5!+ 0(4 Q0    ( .*#PE;9&O0@KA8  "^)
M   1              "  8(7  !D-3$R,CDP9&5X,3 Q+FAT;5!+ 0(4 Q0
M   ( .*#PE97MD A,XX  &+> @ 0              "  5\N  !D-3$R,CDP
M9&5X,3$N:'1M4$L! A0#%     @ XH/"5JH4"&:7"@  R20  !
M     ( !P+P  &0U,3(R.3!D97@U,2YH=&U02P$"% ,4    " #B@\)6@H.A
M; (/  "^,0  $0              @ &%QP  9#4Q,C(Y,&1E>#DY,2YH=&U0
M2P$"% ,4    " #B@\)6E(4;GC\#  !."P  $0              @ &VU@
M;'AR>"TR,#(S,#4S,2YX<V102P$"% ,4    " #B@\)6!WWY(GD&  "X1@
M%0              @ $DV@  ;'AR>"TR,#(S,#4S,5]L86(N>&UL4$L! A0#
M%     @ XH/"5F@C(^O !   0"P  !4              ( !T.   &QX<G@M
F,C R,S U,S%?<')E+GAM;%!+!08     "  ( /L!  ##Y0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
